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1. Abstract 
 
1.1. Zusammenfassung 
 
In der Biochemie definiert der Term „Multivalenz“ ein Konzept von gleichzeitigen und mehrfachen 
Erkennung-/Bindungsereignissen zwischen zwei (makro-)molekularen Gegenstücken. Da es sogar bei 
moderat potenten Liganden eine verbesserte Bindungsstärke ermöglicht, hat dieses Konzept weite 
Anwendung in der biomolekularen Entwicklung und dem Wirkstoffdesign gefunden. In der 
vorliegenden Arbeit, deren Fokus auf der Entwicklung multivalenter Modulatoren von biologischen 
und biotechnologischen Prozessen lag, wurde die Oligomerisierung funktioneller Moleküle durch die 
genetische Fusion oder enzymatische Kopplung mit Oligomerisierungsdomänen sowie durch eine 
nicht-kovalente coiled-coil Interaktion modifizierter Proteine mit multivalenten Biopartikeln erreicht. 
Die in den drei begutachteten Publikationen des kumulativen Teils zusammengefassten Ergebnisse 
dieser Doktorarbeit liefern einen Beitrag zu den synthetischen und biotechnologischen Werkzeugen 
und Methoden zur Generierung von multivalenten Architekturen mit maßgeschneiderten 
Eigenschaften. Diese Studie kann konzeptionell in zwei unabhängige Forschungszweige unterteilt 
werden. Der Erste behandelt die Erforschung von Aviditäts-Effekten durch die Gerüstmolekül-basierte 
Oligomerisierung von therapeutisch relevanten Zielmolekül-bindenden Molekülen. Im zweiten Teil 
steht die Immobilisierung orthogonaler, biokatalytischer Kaskaden auf Biopartikeln im Mittelpunkt. 
In einer vorangegangen Forschungsarbeit wurde gezeigt, dass modifizierte Cystinknoten-Miniproteine, 
basierend auf dem Trypsin-Inhibitor McoTI-II aus der Kürbispflanze Momordica cochinchinensis, in 
der Lage sind, ein therapeutisch relevantes Zielmolekül, das cytotoxic T lymphocyte antigen 4 (CTLA-
4), zu binden, jedoch mit geringer Affinität. Die Potenz dieser Binder kann entweder über aufwändige 
und langwierige Affinitätsmaturierung oder durch die Nutzung von Aviditätseffekten mittels 
Multimersierung verbessert werden. Im Rahmen dieser Arbeit wurden Bindemoleküle peptidischer 
Natur, unter diesen spezielle Oligopeptide und Cystinknoten-Miniproteine, durch genetische Fusion an 
oligovalente Gerüstproteine angebracht. Die Oligomerisierung des niedrig affinen CTLA-4 Binders, 
Cystin-Knoten MC-CT-010 (Kd = 3,7 µM), mit dem Fc-Teil des humanen IgG und der C-terminalen 
Oligomerisierungsdomäne des humanen C4b-Bindeproteins (C4BP) führte zu einer signifikanten 
Verbesserung der funktionellen Bindeaffinität. Insbesondere wurde für das heptavalente 
Fusionskonstrukt, bestehend aus dem C4BP Gerüstmolekül und dem Binder MC-CT-010, eine mehr 
als 400-fach verbesserte Kd von 8 nM erreicht. 
Um das Repertoire an Oligomeriserungsmethoden zu erweitern und eine modulare Anpassung 
multivalenter Architekturen zu ermöglichen, wurden funktionelle Moleküle mit den gewünschten 
oligovalenten Gerüstmolekülen durch eine Enzym-katalysierte Konjugation verknüpft. Hierzu wurde 
das Fc- und C4BP-Gerüstmolekül N- und/oder C-terminal mit peptidischen Erkennungssequenzen 
funktionalisiert, um eine anschließende Sortase A-katalysierte Ligation mit den Liganden von Interesse 
zu ermöglichen, welche das passende Gegenstück tragen. Diese Lego®-artige Strategie erlaubt eine 
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schnelle Enzym-vermittelte Konjugation von funktionalen Monomeren an gewünschte Positionen am 
jeweiligen Gerüstmolekül. Durch die Anwendung dieser Strategie auf Todesrezeptor 5 (DR5) 
targetierende Peptide (DR5TPs) und die modifizierten Fc- und C4BP-Strukturgerüste, konnten dimere, 
tetramere und heptamere Konstrukte mit verbesserter Bindeeigenschaft gegenüber DR5 erzeugt 
werden. Diese Ergebnisse sind besonders im Bezug auf DR5 von Relevanz, da dieser auf Tumorzellen 
überexpremiert wird und durch seine Quervernetzung eine apoptotische Signalkaskade ausgelöst wird, 
die zum Zelltod führt. Interessanterweise wurde die stärkste Bindung an DR5 in vitro beobachtet, 
wenn DR5TP Liganden linear mit den Carboxytermini von C4BP verknüpft wurden. Des Weiteren 
zeigte das funktionalisierte Heptamer eine bemerkenswerte biologische Aktivität. Es induzierte 
Apoptose in lebenden COLO205 Tumorzellen bei einer effektiven Konzentration (EC50) von 3 nM. 
Wir konnten feststellen, dass die Ligandenzahl pro Gerüstmolekül sowie die räumliche Orientierung 
wesentlich für die biologische Aktivität von DR5-targetierenden Oligomeren sind. Im Allgemeinen 
ermöglicht die neu etablierte Plattform die schnelle Oligomerisierung funktioneller Proben und 
erleichtert eine Untersuchung des Einflusses von sterischen Faktoren und der Ligandendichte auf die 
Bindekapazität und Bioaktivität.  
Zusätzlich zu kovalent verknüpften oligomeren Konstrukten wurde eine nicht-kovalente Interaktion 
verwendet, um Enzym-beladene Biopartikel herzustellen und damit Biokatalysatoren für 
Kaskadenreaktionen in hoher Dichte und enger räumlicher Nachbarschaft auf einer Gerüstoberfläche 
zu platzieren. Die Trägerpartikel wurden von einem rekombinanten Polyhydroxyalkanoatsynthase 
(PhaC)-Fusionsprotein abgeleitet und präsentieren eine Vielzahl an negativ geladenen Ecoil-Helices 
auf ihrer Oberfläche. Die Immobilisierung einer enantioselektiven NADH-abhängigen 
Alkoholdehydrogenase aus Rhodococcus erythropolis und einer Formiatdehydrogenase aus Candida 
boidinii wurde durch die Interaktion ihrer aminoterminal angefügten Kcoil-Domänen mit dem 
entsprechenden Ecoil-Gegenstück auf der Oberfläche von PhaC-Partikeln erreicht. Das resultierende 
multimere und multifunktionelle System ermöglicht eine katalytische Kaskade für die stereoselektive 
Produktion von chiralen Alkoholen aus Ketonen – ein wichtiger Schritt in der Herstellung von 
Pharmazeutika und Feinchemikalien. Im Rahmen dieser Studie wurde die Präsenz von immobilisierten 
Proteinen auf den PhaC-Partikeln durch Rasterkraftmikroskopie ermittelt. Die Kaskadenreaktion auf 
der Partikeloberfläche wurde ebenfalls analysiert. So wurde ein vollständiger Umsatz von p-
Chloroacetophenon zu (S)-4-Chloro-α-methylbenzylalkohol durch ADH bei paralleler Regenerierung 
des Kofaktors durch FDH mittels GC-MS Analyse der Reaktionsprodukte nachgewiesen. Des 
Weiteren wurde die Enantioselektivität der ADH durch die Immobilisierung auf den Partikeln nicht 
beeinträchtigt, wie GC-MS Analysen mit einer chiralen stationären Phase zeigten (ee > 99 %). 
Interessanterweise erlaubte die Verwendung eines wässrig-biphasischen Systems die Verwendung von 
konzentrierten Lösungen des hydrophoben Substrates in organischen Lösemitteln. Zusätzlich kann das 
Multienzymkonstrukt einfach an den jeweiligen funktionellen Prozess angepasst werden, da die 
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aktiven Komponenten in verschiedenen Verhältnissen präsentiert werden können und ihre 
Orientierung durch die Positionierung der coiled-coil Komponente gesteuert werden kann. 
 
1.2. Abstract 
 
In Biochemistry, the term “multivalency” defines a concept of simultaneous, multiple 
recognition/binding events between two (macro)molecular counterparts. Enabling enhanced binding 
strength even in the case of intrinsically moderate-potent ligands, this concept has found rather wide 
application in biomolecular engineering and drug design. In the present work, focused on the 
development of multivalent modulators of biological and biotechnological processes, oligomerization 
of functional biomolecules was achieved by their genetic fusion or enzyme-mediated ligation to 
oligomerization domains, as well as by non-covalent coiled-coil interactions of modified proteins with 
multivalent bioparticles. Summarized in three peer-reviewed publications given in the cumulative part, 
the results of this doctoral research contribute to the toolbox of synthetic and biotechnological methods 
for the generation of multivalent architectures with tailor-made properties. Conceptually, the study can 
be separated into two independent research branches, the first one exploring effects of avidity by 
scaffold-based oligomerization of therapeutically relevant target-binding molecules, and the second 
one dealing with immobilization of orthogonal biocatalytic cascades on bioparticles.  
In our previous investigation it was shown that engineered cystine-knot miniproteins based on the 
scaffold of trypsin inhibitor McoTI-II from the squash plant Momordica cochinchinensis are able to 
bind a therapeutically relevant target, namely cytotoxic T lymphocyte antigen 4 (CTLA-4), however, 
with low affinity. The potency of these binders can be improved either applying rather sophisticated 
and time-consuming affinity maturation, or by inducing avidity effects upon multimerization. The 
latter approach was considered in the present work due to the fact that dimeric CTLA-4 protein is 
presented on the cell surface in high copy numbers. Within the frame of this work, binding molecules 
of peptidic nature, among them particular oligopeptides and cystine-knot miniproteins, were attached 
to oligovalent scaffold proteins by genetic fusion yielding stable oligomers upon recombinant 
expression. As expected, oligomerization of low-affinity CTLA-4 binder cystine knot MC-CT-010 (Kd 
= 3.7 µM) on the Fc part of human IgG and the C-terminal oligomerization domain of human C4b 
binding protein (C4BP) lead to a significant improvement of its functional binding affinity. Indeed, a 
more than 400-fold improved Kd of 8 nM was determined for the heptavalent fusion construct 
comprising the C4BP scaffold and MC-CT-010 binder. 
In order to extend the repertoire of oligomerization methods and to ensure tailoring of multivalent 
architectures in a modular way, enzyme-catalyzed conjugation of functional molecules with the 
desired oligovalent scaffolds was applied. To this end, the Fc and C4BP scaffolds were N- or/and C-
terminally functionalized with peptidic recognition tags enabling subsequent sortase A-catalyzed 
ligation with the ligands of interest bearing a respective counterpart. This Lego®-like strategy allowed 
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for the fast enzyme-promoted conjugation of functional monomers at the desired positions within the 
scaffold. Being applied to death receptor 5 (DR5) targeting peptides (DR5TPs) and the modified Fc 
and C4BP scaffolds, this approach yielded dimeric, tetrameric and heptameric constructs possessing 
improved binding capacity towards DR5. These results are of special value as DR5 is overexpressed 
on cancer cells and, being crosslinked, induces an apoptotic signaling cascade. Interestingly, the 
strongest binding to DR5 in vitro was observed when the DR5TP ligand was attached to the 
carboxytermini of C4BP in a linear fashion. Furthermore, this engineered heptad revealed a 
remarkable biological activity, being able to specifically induce apoptosis in living COLO205 cancer 
cells (EC50 = 3 nM). We ascertained that ligand number per scaffold molecule as well as their position 
and spatial orientation is crucial for the biological activity of DR5-targeting oligomers. In general, the 
established platform allowed for the fast oligomerization of functional probes with further 
investigation of the steric factors, as well as issues of ligand density, which can influence binding and 
bioactivity.  
In addition to covalently bound oligomeric constructs, a non-covalent coiled-coil interaction was used 
to fabricate enzyme-loaded bioparticles able to promote orthogonal biocatalytic cascades. The carrier 
particles were derived from a recombinant polyhydroxyalkanoate synthase (PhaC) fusion protein, 
displaying a multitude of negatively charged Ecoil helices on their surface. Immobilization of 
enantioselective NADH-dependent alcohol dehydrogenase from Rhodococcus erythropolis and a 
formate dehydrogenase from Candida boidinii was achieved through the interaction of their 
engineered Kcoil domains with the respective Ecoil counterpart on the surface of PhaC particles. The 
resulting multimeric, multifunctional system enabled a catalytic cascade for the stereoselective 
production of chiral alcohols from ketones – an important step in the manufacturing of 
pharmaceuticals and fine chemicals. In the frame of our study, the presence of immobilized proteins on 
PhaC particles was revealed by atomic force microscopy imaging, and the resulting system appeared 
fully functional. Thus, complete conversion of p-chloroacetophenone to (S)-4-chloro-α-methylbenzyl 
alcohol by ADH with parallel cofactor regeneration by FDH was confirmed by GC-MS analysis of the 
reaction products. Moreover, the enantioselectivity of ADH was not affected by the immobilization 
onto the particles, as was confirmed by GC-MS analysis applying the chiral stationary phase 
(ee > 99 %). Interestingly, application of an aqueous biphasic system allowed us to use highly 
concentrated solutions of hydrophobic substrates in organic solvents. In addition, this multienzyme 
construct could be easily tailored depending on the functional task as the active components could be 
presented on bioparticles in different ratios, and their orientation can be controlled by the position of 
the coiled-coil components. 
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2. Introduction 
 
2.1. Multivalency in Nature 
 
Multivalency is a concept that Nature often uses to strengthen reversible interactions, thus enhancing 
their efficacy.1 The burdock seeds which gave rise to a common cliché “stick like a bur” are a vivid 
example for this phenomenon. Indeed, while each single hook located on the seed provides a 
negligible hitching, their manifold assures strong cohesion (Figure 1). On the molecular level, the 
similar multivalent interactions between myosin and actin filaments govern the contraction of muscles. 
Further, multimeric architecture often leads to higher stability and improved substrate affinity of 
certain enzymes as well as to the enhancement of their rigidity and thermostability.2,3 
Regarding the human immune system, multivalency plays an important role as the first line of defense 
against invading pathogens relies strongly on this concept. Indeed, the components of the innate and 
adaptive immune response that interact with pathogens upon the early phase of a primary immune 
response are often multivalent molecules. Thus, the immunoglobulin M (IgM), which is produced as 
the first immunoglobulin within two to three days after initial exposure to an antigen, is secreted in two 
functional forms: as a pentameric antibody joined by a J (joining)-chain with ten antigen-binding sites 
or as a hexameric one possessing twelve antigen-binding sites and lacking the J chain (Figure 2).4 IgM 
is found both in the blood (0.6 - 2.4 mg/ml serum concentration) and on the surface B-cells as a 
membrane-bound antigen receptor. It is active against invading microorganisms and acts as a major 
activator of the complement system. Compared to matured IgG molecules that underwent somatic 
hypermutation and class switching initiated upon antigen contact with a membrane-bound IgM 
molecule on B-cells, these penta- and hexameric molecules have rather weak intrinsic binding 
affinities. However, functional binding of IgM to the antigens on the surface of invading 
 
Figure 1: (left) Sketch of burdock plant Arctium lappa  modified from Kops et al., J., Flora Batava, vol. 4: t. 254 (1822). 
(right) Close up of Velcro fastener inspired by the burdock. Modified from National  
Geographic “Biomimetik” (2008). Picture: Robert Clark  
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microorganisms is strongly enhanced upon multimerization (even though not all 10 or 12 antigen-
binding sites can bind simultaneously due to steric hindrances). Interestingly, immunoglobulin A (IgA) 
forms dimeric and, to a lesser extent, trimeric or tetrameric antibody constructs joined by a J-chain 
with 4-8 antigen-binding sites (Figure 2). IgA, the second most abundant immunoglobulin found in the 
blood, is the most dominant Ig isotype in body fluids like saliva, sudor, breast milk, urogenital and 
bronchial secrete where it disables attachment of viruses and bacteria to epithelial cells. Due to its 
tetra- to octavalent architecture it is able to address multiple antigens at the same time, which allows a 
stronger interaction with pathogens. All further isotypes, namely IgG, IgD, IgE, mIgM (membrane-
bound IgM) and mIgA (membrane-bound IgA) antibodies are bivalent molecules possessing two 
antigen-binding sites (Figure 2).  
Multivalent binding can regulate complement-dependent cytotoxicity, as exemplified by the hexameric 
complement factor C1q. Per se, it has a rather low binding affinity of 100 µM towards singular IgG in 
serum.5 However, upon clustering of IgG molecules in immune complexes the functional affinity of 
C1q increases to 1 µM for IgG dimers and to 3 nM for IgG trimers, which leads to complement 
activation by the classical pathway.6 In broader terms, multivalency has an important advantage 
regarding the multiplicity of identical antigens on the surface of pathogens like bacteria, viruses, or 
degenerated cells, being therefore an important element of immunity.7 In the matter of fact, due to the 
(at least) bivalent binding mode the resulting avidity of such molecules is strongly enhanced compared 
to the specific/intrinsic affinity of a solitaire binding unit.  
 
Figure 2: Hierarchy of immunoglobulin isotypes. IgA, IgD, IgE, IgG and IgM are human immunoglobulin isotypes that are 
determined by their heavy chain. IgA is the most abundant antibody in body secretions (saliva, tears, colostrum and mucus) 
and the second most abundant immunoglobulin in the blood. IgA monomers are present in the blood while dimers (joined 
by a J-chain), trimers and even tetramers can be found in body secretions that provide local immunity. Membrane bound 
IgD serves as an antigen receptor on the surface of B-lymphocytes, while the role of soluble IgD in plasma is unknown. IgE 
build the main defense against parasites and are mainly responsible for anaphylactic hypersensitivity reactions in humans. 
IgG is the most prominent antibody in the plasma and has the longest half-life (23 days) in comparison to the other 
immunoglobulins. IgG can cross the placenta and permeate into the extravascular space. It induces CDC and ADCC after 
opsonization of pathogens. IgM exists as a pentameric molecule joined by the J-chain and as a hexamer, which is lacking 
the J-chain. IgE and IgM carry an additional CH2 domain in place of the hinge region, which connects the two heavy 
chains.8 
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In this work, the specific or intrinsic affinity is defined as the energetic relationship between a single 
binding site and its corresponding antigen, while the functional affinity (avidity) is the enhancement of 
binding strength upon multivalent interactions.7,9  
 
2.2. Target-binding molecules 
 
Generally, antibodies possess 
a Y-shaped structure and 
comprise two pairs of 
identical heavy, respectively 
light chains. The variable 
regions of an antibody that 
mediate antigen binding are 
called complementary 
determining regions (CDRs) 
and located within the tips of 
the heavy and light chains. 
Disulfide bonds connect two 
heavy chains and assure 
covalent linkage between the 
heavy and the corresponding 
light chains (Figure 3). The 
effector functions of an IgG 
are located within the 
crystallizable Fc domain. 
The Fc part mediates 
complement-dependent cytotoxicity (CDC) by binding to C1q. It is also able to bind to Fc gamma 
receptors (FcγR) on immune effector cells, among them natural killer cells, thus inducing antibody-
dependent cellular cytotoxicity (ADCC). Further, the Fc part of IgG interacts with the neonatal Fc-
receptor (FcRn) leading to recycling of internalized IgGs and long, up to 7-23 days, circulation times. 
Therapeutic monoclonal antibodies have two modes of action. They bind to a specific antigen on a 
particular cell and mediate CDC and ADCC by the Fc-part or they bind to a specific antigen and 
antigen binding mediates a certain signal, e.g. apoptosis, or blocks signaling, e.g. binding to growth 
factors. Though the first monoclonal antibodies (mAbs) have been recombinantly produced in 
eukaryotic cells in 1975,10 the complex structure of these proteins and the requirement of post-
translational modifications, e.g. glycosylation, render their recombinant production rather difficult, 
especially in prokaryotic hosts.  
 
Figure 3: Basic structural components of an antibody. The Y-shaped 
immunoglobulin consists of two heavy chains (grey) and two light chains 
(orange). The variable domains (VH and VL domain; Fv fragment) of each chain 
can contribute to antigen binding. The Fc fragment can mediate the effector 
functions ADCC and CDC. Pepsin cleavage of an IgG reveals a bivalent F(ab)2 
fragment, while papain cleavage reveals monovalent Fab fragments consisting of 
the light chain and parts of the heavy chain (CH1 and VH) joined by a single 
disulfide bond. The constant domain of the heavy chain of an immunoglobulin 
determines the isotype (IgM, IgG, IgA, IgD or IgE), effector functions and tissue 
localization. 
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However, some intrinsic characteristics of antibodies - ADCC, CDC, and long circulation times - can 
become undesired for particular applications. For example, the large size (150 kDa) of antibodies leads 
to an impaired tumor penetration in the case of solid tumor associated targets. To that end, several 
attempts have been made to reduce the complexity of antibodies by their disassembly towards less 
structurally sophisticated functional units. Thus, proteolytic digestion of IgG molecules with papain or 
pepsin resulted in the binding constructs comprising the light chain, a part of the heavy chain (VH and 
CH1) and, in case of pepsin digestion, a partial hinge region (Fab)2 (Figure 4). Monovalent fragments 
lacking the hinge chain, called Fab fragments (55 kDa; Figure 4), can be accessed by papain digestion 
of full-length IgG or produced as recombinant Fab fragments in prokaryotic hosts like Escherichia 
coli. A further minimization leads to single chain variable fragments (scFv; 25 kDa) (Figure 4). They 
merely consist of the variable fragments of the antibodies light and heavy chain (VL and VH, 
respectively) connected by an engineered peptidic linker. Fab and scFv retain their antigen binding 
abilities, albeit with a reduced, compared to bivalent antibodies, functional affinity due to their 
monovalent mode of interaction. These functional fragments made a significant contribution to modern 
screening technologies, among them phage and yeast display.  
Alternatively to human antibodies, sharks and camelids possess antibodies that lack light chains. The 
shark- and camelid-derived variable domains are called vNAR (variable domains of immoglobulin 
new antigen receptor, IgNAR) and VHH (also called nanobodies), respectively (Figure 4) and can be 
produced as solitaire monovalent binders. Comprising exclusively the variable heavy chain domains, 
these molecules are even smaller than scFv (12-15 kDa compared to 25 kDa) and demonstrate 
particular stability.11  
In addition to antibody-derived target-binding units, non-immunoglobulin-derived binding structures 
have been to date engineered, among them cystine knots12, adnectins13 (10th human fibronectin type III 
domain), affibodies14 (reengineered protein A domain), anticalins15 (lipocalin), ankyrin repeats 
(DARPins)16 and avimers17 (avidity multimer derived from certain cell-surface receptors). These 
compounds are proteins or peptides with a stable and conserved protein or protein-mimicking 
framework with variable loop segments that can be altered/randomized to recognize different target 
molecules.14 Such non-immunoglobulin binders are rather small (Figure 5) 4 kDa for avimers, 14 kDa 
 
 
Figure 4: Antibody fragments. Bivalent F(ab)2 fragments can be generated by pepsin cleavage of an immunoglobulin. 
Monovalent Fab fragments can be produced by papain cleavage or recombinantly produced. Single chain variable 
fragments (scFv; 25 kDa) contain the variable domain of the heavy and light chain joined by 15 aa linker. vNAR and 
vHH (15 kDa) are the variable fragments of heavy-chain(-only) antibodies from cartilaginous fish and camelidae. 
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for DARPins, affibody 6.5 kDa, adnectins 10 kDa, anticalins 20 kDa, cystine knots 3-5 kDa) and can 
be combined or further engineered into multispecific or/and multivalent molecules.14 
 
Figure 5: Scheme of non-immunoglobulin binding molecules. Cystine knot (3-5 kDa, PDB-ID: 2IT8), Avimer (avidity 
multimer derived from certain cell-surface receptors, 4 kDa, this work), Affibody (reengineered protein A domains, 
6.5 kDa, PDB-ID: 2M5A), Adnectin (10th human fibronectin domain, 10 kDa, PDB-ID: 3QWR), DARPin (ankyrin repeats, 
14 kDa, PDB-ID: 4YDW), Anticalin (lipocalin, 20 kDa, PDB-ID: 4MVI). 
In detail, cystine knots peptides share a common “pseudo-knotted” architecture, which is directed by 
three disulfide bonds.12 Typical structural motifs of cystine knots are three antiparallel β-strands 
connected by short loops, which can differ in size and amino acid composition.18 
Small- to medium-size peptides comprising 5-50 amino acid residues are the smallest proteinaceous 
target-binding molecules.19 In general, therapeutic peptides can be derived from those occurring in 
Nature and produced by humans, animals or plants (hormones and fragments of proteins), developed 
using screening approaches or engineered by rational design.19 They can be accessed using both 
recombinant production and chemical assembly, e.g. solid-phase peptide synthesis (SPPS). The latter 
allows chemical modifications, among them introduction of non-natural elements, branching, 
orthogonal side-chain elongations, macrocyclizations, or labeling. Using these technologies, a plethora 
of peptides acting against tumor-related targets has been generated.19 However, their small size 
narrows the binding interface and only very few amino acids can contribute to the interaction with a 
target, thus leading to moderate binding strength.  
Molecular size, charge, affinity, stability, specificity, and valency – these are the factors which 
influence biodistribution and pharmoacokinetics of antibodies targeting tumor-related antigens.20 
Therefore it is rather obvious that the above-mentioned specific antigen binding molecules are not 
fully optimal for therapeutic applications due to their size-associated fast blood clearance. However, 
they can serve as building blocks for the generation of larger molecules.  
 
2.3. Multimerization strategies 
 
Obviously, small size of a binding molecule is an advantage upon tumor penetration. However, 
monovalent antibody fragments, e.g. single chain variable fragments (scFv), nanobodies (VHHs) or 
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shark heavy chain antibody fragments (vNARs) generally suffer from short circulation time due to fast 
renal clearance.20-22 Though engineering of these antibody fragments can yield highly affine binders, 
strong binding capacity and a high local density of antigens can also lead to a decrease in tissue 
penetration when it comes to a situation called “binding site barrier”.23 Indeed, at high local 
concentration of an antigen the ligand, being steadily bound and rebound, retains in the close 
proximity to the target, thus affecting its distribution in the tumor. To overcome this handicap, rather 
high concentration of the ligand is required. 
A comprehensive study with several scFv possessing diverse affinities towards the same target (high 
nanomolar to low picomolar dissociation constants) revealed that the most potent constructs lacked 
selectivity upon tumor targeting and showed impaired tumor penetration.24 In comparison, the 
construct with rather moderate potency (one-digit nanomolar) showed the best selectivity and tumor 
retention, while for the mutant with three-digit nM Kd the most uniform tumor distribution was 
observed. Nonetheless, in a non-equlibirum environment of human tissue these monovalent antibody 
fragments suffer from moderate target retention due to the fast dissociation of the binders. In an 
optimal therapeutic molecule, an appropriate compromise must be established between optimal tumor 
penetration (considering molecular weight), functional affinity, and reasonable serum half-life.9  
Enhancement of the binding strength of target binding molecules without compromising their antigen 
specificity is a challenging task.25 To that end, affinity maturation represents an established but time-
consuming method. As an alternative, small monovalent binding molecules can be engineered towards 
the intrinsic multivalent format of antibodies. Thus, the target binding strength of small antibody 
fragments can be significantly improved by increasing the number of antigen binding sites. 
Multimerization additionally leads to a prolonged circulation time due to the higher molecular weight 
and longer retention time at target tissues caused by the forced proximity of the binding moieties and 
slower off-rates. The improved half-life and enhanced functional affinity allows the usage of lower 
doses and results in reduced costs and dose-dependent side effects.26 
 
2.3.1. Linkers and linear fusion  
To date, several strategies have been developed for the multimerization of scFv and single domain 
antibodies (VHHs and VNARs). Diabodies, triabodies and tetrabodies are composed of scFv 
molecules with a shortened linker between the variable light and heavy chain.27 Such a shortened 
linker prevents intramolecular pairing of the variable light and heavy chains and enables the assembly 
of two individual scFv to form diabodies. Depending on the linker length and orientation of the 
variable domains, further shortening can lead to pairing of scFv molecules towards tria- or even 
tetrabodies. This phenomenon is called domain swapping. A further possibility to produce bivalent 
scFvs is their linear gene fusion. This approach was initially developed for the production of bispecific 
scFv of the bispecific T-cell engager (BiTE) format.28 Simultaneous binding of BiTEs to a targeted 
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antigen on tumor cells (e.g., CD19; blinatumomab) and CD3 on T-cells has demonstrated a high 
potency on B-cell malignancies in clinical studies, which convinced the FDA to approve 
blinatumomab for the treatment of patients with acute lymphoblastic leukemia.29,30 In addition, linear 
gene fusion can also be applied to generate scFab and bivalent (scFab)2.31  
Linear gene fusion also plays an important role for the multimerization of VHH nanobodies. As these 
constructs comprise a single domain, oligomerization can be achieved simply by introduction of a 
coding sequence for a linker module between the coding sequence of nanobodies possessing the same 
as well as different specificity.32 Thus, upon the multimerization of a DR5-targeting nanobody a 
trimeric construct was able to mimic the activity of the natural ligand TRAIL, while increasing the 
valency to tetramers and pentamers further enhanced the biological activity of the nanobody on tumor 
cells.33 However, a clinical phase I study with the tetravalent construct TAS266 was aborted due to 
unexpected hepatotoxicity.34 As another example, the trivalent bispecific nanobody ozoralizumab 
(ATN-103) binds to albumin for plasma half-life extension and neutralizes TNFα. It is currently 
investigated in a clinical phase II trial for the treatment of rheumatoid arthritis.35 
Interestingly, linear fusion is generally not applicable to shark vNAR single domain antibodies. The 
tandem linkage of two vNAR domains did not result in bivalent binding to an antigen as only the N-
terminal vNAR of the construct contributed to antigen binding.36 
 
2.3.2. Scaffold molecules 
 
As an alternative to the linear fusion, target binding molecules can be fused to multivalent scaffold 
molecules to achieve multivalency. Fusion to multivalent scaffolds has several advantages, among 
them the prolonged target residence time which can be achieved when multiple ligands bind to their 
target site due to the forced proximity of the ligands. In this case a bound ligand brings the residual 
scaffold-associated counterparts into close proximity to the binding sites on the targeted cell, thus 
favoring both their binding and the rebinding of dissociated ligands.37 This of course strongly depends 
on the distribution of targeted molecules in close proximity. 
For clarification: the term “scaffold” can specify two subjects, a non-immunoglobulin binder 
consisting of a stable and conserved protein framework with variable segments that can be altered to 
recognize different target molecules (i.e. nanobodies, cystine-knot peptides and ankyrin repeats) or a 
molecule of synthetic or natural origin with a defined architecture for the multivalent display of 
functional units.38 The latter can be chemical scaffolds, i.e. cyclic decapeptides and adamantane-based 
dendrons, or proteinaceous ones, i.e. C4BP, COMP, leucine zippers, TNF, GCN4, p53, Sm1 and 
streptavidin (Table 1).20,25 
Scaffold molecules applied for multimerization should possess certain attributes: small size, defined 
architecture, high stability, low tendency to aggregate, sufficient solubility in aqueous solutions and 
modification sites that can be addressed without affecting the integrity of the scaffold. 
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2.3.3. Ig-like formats 
In scaffolds that imitate immunoglobulins, referred to as Ig-like formats, dimerization of binders (i.e. 
scFv, Fab and VHH) occurs upon self-assembly of a fused constant light (kappa) or heavy chain 
domain. For this purpose constant domains of different Ig isotypes have been to date engineered. 
Fusion of scFv or peptides to the Fc domain of IgG has been used to generate bivalent and even 
tetravalent constructs that exhibit enhanced functional affinities as well as Fc effector functions and 
possess long circulation time (1-2 weeks) due to conserved FcRn binding and the higher molecular 
weight.39-41 Notably, Fc peptide fusions (also termed peptibodies) have been found to be potent drugs 
with good pharmacokinetic characteristics and manufacturability.40 In 2008, the peptibody 
Romiplostim (brand name Nplate) was approved for the treatment of immune thrombocytopenic 
purpura by the FDA.40 Further, scFv have been fused to CH3 of IgG through a hinge region as a 
flexible disulfide-bridged linker.42 These bivalent molecules are termed minibodies and possess an 
intermediate size of 80 kDa, which is above the molecular mass cutoff for glomerular filtration (30 – 
50 kDa) and leads to elongated circulation times, improved tumor targeting and biodistribution 
properties in in vivo xenograft studies when compared to scFv and diabodies.42 In a similar approach, 
the CH2 domain of IgM (MHD2) has been applied as a scaffold for dimerization and even 
tetramerization of scFv. The MHD2 domain self assembles into a dimer covalently stabilized by an 
intermolecular disulfide at cysteine 337.8 The authors generated monospecific bivalent and bispecific 
tetravalent scFv fusion proteins which exhibited binding to their respective antigens. Tetravalent 
bispecific molecules were generated by the fusion of EGFR-specific scFv to the N-terminus of MHD2 
and HER2-specific scFv − to its C-terminus.8 A similar study was performed by the same group using 
the CH2 domain of IgE, which showed an improved stability in comparison to the MHD2 dimerization 
domain due to a second disulfide bond.43 Again, bispecific tetravalent proteins were constructed by 
fusion of an EGFR-specific scFv to the N-terminus of EHD2 and a single-chain TRAIL variant 
(scTRAIL) − to its C-terminus. The targeted delivery of this molecule showed improved in vivo 
antitumor activity in a xenograft study.43 
In addition, the human constant kappa light chain domain has been used for the dimerization of a 
tumor necrosis factor alpha (TNFα) specific VHH.44 As expected, the bivalent molecule inhibited 
TNFα-mediated cytotoxicity more efficiently than the monovalent precursor.44 
 
 
2.3.4. Oligomerization domains (multivalent scaffolds) 
In addition to immunoglobulin-imitating formats, several multivalent scaffolds were applied for the 
multimerization of binding moieties. Fusion to oligomerization domains has been found to increase the 
half-life of the fusion partners, thus enabling their activity for a prolonged period.26 The activity of 
multimeric functional biomolecules is enhanced because of a stronger target binding due to avidity 
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rather than affinity. Moreover, they possess 
the improved ability to cross-link molecules 
i.e. of identical receptor subunits as in the 
case of TNF or the insulin receptors which 
are activated upon multimerization.26 TNFα is 
a trimeric cytokine (Figure 6) that was used 
as a scaffold for the trimerization of a scFv 
that binds to the extradomain B (ECB) of 
fibronectin. The construct showed slow off-
rates, accumulated selectively at the targeted 
tumor and mediated an improved anticancer 
response than untargeted TNFα.45 
Interestingly, in the treated mice it even 
retarded regrowth of tumors, which indicated 
the induction of an antitumor vaccination 
effect.46,47  
Streptavidin (Figure 6) has been used for 
tetramerization of scFv upon genetic fusion 
of a scFv and the core-streptavidin coding 
sequence.48 The fusion protein was 
recombinantly produced as inclusion bodies 
in the periplasm of E. coli cells. After 
refolding towards the tetrameric format, the 
construct showed enhanced target binding 
due to avidity effects and remained its biotin 
binding capacity.48 Plückthun and coworkers 
constructed different tetravalent 
miniantibodies using the multimerization 
peptide of p53 as well as a mutated coiled-
coil domain of the transcription factor GCN4 
(Figure 6), which forms tetramers instead of 
the original dimers.49,50 With the size of a 
bivalent F(ab)2, the tetrameric GCN4 
construct showed higher functional affinity 
than the dimeric one.49 Later, the same group used the ribonuclease barnase (12 kDa) and its inhibitor 
barstar (10 kDa) (Figure 6) for di- and even trimerization of HER2-specific scFv.51 Expressed as 
monomers and subsequently mixed, barnase and barstar formed heterodimeric complexes with a Kd of 
 
Figure 6: Non-immunoglobulin multimerization domains. 
Heterodimerization domain barster-barnase (PDB-ID: 2ZA4), 
homodimerization domain GCN4 leucine zipper (PDB-ID: 
4DMD), trimerization domain TNFα (PDB-ID: 1TNF), 
leucine zipper tetramerization domain (PDB-ID: 2NRN), 
streptavidin core tetramerization domain (PDB-ID: 3RY1), 
COMP pentamerization domain (PDB-ID: 3V2N), 
heptamerization domain Sm1 (PDB-ID: 1I4K) and 
heptamerization domain C4BP (PDB-ID: 4B0F). 
 Introduction   16 
10-14 M, which is comparable to the interaction of streptavidin with biotin (10-15 M).51 The dimeric 
scFv were generated by the fusion of a scFv to each of these domains, while trimeric scFv constructs 
were achieved by head-to-tail junction of two barnase molecules (scFv-barnase-barnase).51  
Composed of at least 46 residues and self-assembling into a parallel disulfide-stabilized pentameric 
structure, the human cartilage oligomeric matrix protein (COMP48, Figure 6) was used for the 
pentamerization of various target-binding molecules.52 A VHH targeting the melanoma peptide HLA-
A2 complex was fused to the N-terminus of COMP48 resulting in a pentameric antibody COMBODY 
that, compared to the monovalent VHH, exhibited an enhanced binding capacity.52 Furthermore, the 
authors generated a bispecific COMBODY by additional fusion of an anti-CD3 scFv to the C-
terminus. Interestingly, the expected bispecific decavalent molecule accumulated to larger aggregates 
that mediated specific cell lysis of peptide-loaded target cells.52 Another group generated a pentameric 
COMP-EGF fusion protein bearing 5 EGF ligands that specifically bound to the extracellular domain 
of EGFR53 on EGFR-overexpressing cancer cells and induced apoptosis.53 This fusion protein was 
produced in E. coli cells but needed extensive refolding due to the complex tertiary structure.53 
Besides COMP, the E. coli verotoxin B subunit (VTB, also termed shiga-like toxin) has been used for 
the pentamerization of a VHH domain that specifically binds the parathyroid hormone (PTH) used for 
the treatment of osteoporosis.54 Compared to the monovalent VHH, such “pentabody” fusion proteins 
(with size about 115 kDa) exhibited 103- to 104-fold improved binding to their target.54 To further 
expand the scope of VTB as an oligomerization scaffold, VHH domains were fused to its N- and C- 
termini yielding a decavalent protein with dual specificity for PTH.55 Different linkers were examined 
within this study, and only a single fusion protein from 15 tested variants did not form aggregates.55  
For the heptamerization of affibody molecules targeting EGFR and HER2, respectively ZEGFR and 
ZHER2, a 70-residue oligomerization domain AF-Sm1 (Figure 6, table 1) from the hyperthermophilic 
organism Archaeoglobus fulgidus was applied.25 The affibody was fused to the N-terminus of Sm1 
with a flexible linker in-between and expressed in E. coli cells. Compared to the monomeric affibody, 
the heptameric molecules showed 100- to 1000-fold higher functional affinities towards their target, 
presumably due to the reduced dissociation rate.25 In a comprehensive study a right-handed coiled-coil 
peptide (RHCC) from an archaebacterium, COMP and the C-terminal oligomerization domain of the 
human C4b binding protein (C4BP) were used for the tetra-, penta- and heptamerization of an EGFR-
binding VHH, respectively.56 Produced in the cytoplasm of E. coli cells, all the constructs showed 
improved EGFR binding and were able to recognize EGFR-expressing cells in vitro. In a follow-up 
study, the EGFR-targeting C4BP fusion protein was radiolabeled with 99mTc and applied for efficient 
in vivo tumor imaging in a xenograft with A431 tumors.57  
The C4BP oligomerization domain (Figure 6, table 1) is derived from a human plasma glycoprotein of 
the complement cascade inhibitor C4b binding protein. The 60 C-terminal residues of this inhibitor 
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fold into an α-helical structure and self-assemble into a heptameric architecture which is further 
stabilized by interchain disulfide bonds.58  
This overview shows that various scaffolds of different origin can be engineered to achieve multivalent 
antigen-binding molecules comprising 2-7 functional ligands. Depending on the desired application 
and the nature and complexity of the binding moiety, one can choose from the variety of scaffolds and 
linkers to generate high-avidity binding molecules.    
 
Table 1: Oligomerization domains used for multimerization of binding domains. 
 
Scaffold Ligand Valency Target Source 
Sm1 affibodies 7 EGFR/ HER2 25 
COMP48 (cartilage oligomeric 
matrix protein) 
peptides/ VHH/ 
scFv/ EGF 
5 EGFR/ BCL1/ melanoma-HLA-
A2 complex/ CD3/ VEGFR 
52 
TNF scFv 3 Extradomain B (ECB) of 
fibronectin 
45 
GCN4 / TETRAZIP scFv 2-4 PC-BSA 49 
Streptavidin scFv 4 unknown 48 
Fc peptides 4 hTPOR, VEGF 40 
Shiga like toxin (subunit of 
E. coli verotoxin) 
VHH 5 Parathyroid hormone PTH 54 
p53 (p53 tumor suppressor 
oligomerization domain) 
scFv 4 tumor-associated carbohydrate 
antigen, HER2 
50,59 
Synthetic dhlx peptide (helix-
turn-helix motif) 
scFv 2 HER2 50 
C4BP peptides/ cystine-
knots / VHH 
7 DR5, CTLA-4/ EGFR 56,60,61 
Right handed coiled coil RHCC VHH 4 EGFR 56 
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2.4. The C4b binding protein and its role in the complement system 
 
The complement system is a part of 
the innate immune system. It activates 
the cellular immune response, marks 
pathogens and necrotic cells for 
removal, and is also able to lyse them 
by forming a membrane attack 
complex (MAC).62 Three different 
routes can initiate the complement 
cascade. The classical pathway is 
induced by the C1 immune complex 
which is composed of C1q, C1s and 
C1r directly bound to a microbial 
surface or to target cell-associated 
IgM or IgG molecules (Figure 7). 
Mannose-binding lectin (MBL) and 
ficolins can recognize particular 
carbohydrate structures on the surface 
of invading pathogens and initiate the 
so-called lectin pathway (Figure 7). In 
addition to the classical and lectin 
pathways, an alternative one can be 
induced by spontaneous hydrolysis and activation of the complement component C3, which can 
directly bind to the pathogens. All the pathways share the general scheme implying the protease C3-
convertase-mediated cleavage of C3 towards C3a and C3b. The latter fragment binds to the surface of 
targeted cells. In the ongoing cascade, a C5 convertase is formed that promotes the cleavage of C5 into 
C5a and C5b.62 C5b also binds to targeted cells and initiates the formation of MAC, a lytic pore that is 
able to kill eukaryotic and gram-negative cells by osmotic lysis.62 Complement inhibitors such as the 
C4BP tightly regulate the process of complement activation to avoid unspecific decay. C4BP is the 
major inhibitor of the classical and lectin pathway since it binds the activated complement component 
C4b and inhibits its function (Fig 7). C4b together with the complement component C2a (C4bC2a) 
forms a C3-convertase that can be cleaved, thus inactivated, by the serine protease factor 1 (F1) in 
presence of the cofactor C4BP (Fig 7).63,64 Further, C4BP accelerates the natural decomposition of the 
C3-convertase and also acts as a cofactor of F1 in the cleavage of soluble C3b upon the alternative 
pathway.65,66  
The C4BP is a 570 kDa glycoprotein which is mainly produced by liver cells and found in the blood at 
a concentration of 200 mg/l.67 It exists in four different isoforms (7α 1β, 6α 1β, 7α, or 6α) whereof the 
 
Figure 7: Scheme of C4BP as the major inhibitor of the classical and 
lectin pathway. The classical pathway is initiated by pathogen bound 
complement component 1 (C1q, C1r and C1s), while carbohydrate-
binding proteins bound to certain structures on the pathogens surface 
initiate the lectin pathway. Upon binding of these structures the 
complement component C4 is recruited and cleaved into C4a and 
C4b. The latter is a component of the C3 and C5 convertase, which 
are important mediators of complement activation. C4BP can inhibit 
complement activation by C4b binding and furthermore acts as a 
cofactor of factor 1 in the cleavage of the C3 convertase. (Inspired by 
Riedermann N. C. iahealth.net). 
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7α 1β–chain type is the most abundant isoform. The α- and β-chains are composed of 8 and 3 
complement control protein (CCP) domains, respectively, and a C-terminal oligomerization domain. 
The β-chain of C4BP binds and inhibits the anticoagulant protein S but is not capable of binding 
C4b.68 C4b binding of the α-chain is mediated by CCP1-3, whereas CCP1-4 are required for C3b 
interaction.66,69 Interestingly, certain pathogens can evade opsonization by the immune system by 
capturing C4BP on their surface.62  
 
2.5. The C-terminal oligomerization domain of the C4BP α chain as a scaffold 
The C-terminal oligomerization domain of each α-chain of the C4BP folds into α-helical structures that 
self-assemble to stable heptameric architectures. The crystal structure of this oligomerization domain 
was recently unraveled and revealed that 7 intermolecular hydrogen bonds, 14 intermolecular salt 
bridges, and 7 intermolecular disulfide bonds are responsible for the extraordinary robustness of this 
biomolecular scaffold.58 The outstanding stability of this heptavalent framework and its human origin 
make the C4BP core domain a perfect candidate as an oligomerization platform for antigen-binding 
molecules. Previous studies have shown the applicability of C4BP as an oligomeric fusion partner. An 
anti-Rh(D) scFv was fused to the C4BP α-chain, which induced polymerization during protein 
synthesis with a Chinese hamster ovary (CHO) cell line and resulted in a covalently linked soluble 
molecule that bound and agglutinated Rh(D)-positive red blood cells.70 In an attempt to generate a 
heterofunctional bispecific molecule that specifically binds to erythrocytes and displays the CR1 
protein (CD35, C3b/C4b receptor), CHO cells were cotransfected with a construct encoding for a CR1-
C4BP fusion protein and a second construct encoding for an anti-Rh(D) scFv-C4BP fusion protein.71 
The secreted protein was able to simultaneously bind to Rh(D)-positive erythrocytes and to capture 
immune complexes by CR1.71 The authors speculated that this heterofunctional molecule could 
possibly restore the immune complex clearance by erythrocytes, which is impaired in some disease 
such as systemic lupus and AIDS. In a study by Christiansen et al., the ectodomain of the human 
membrane cofactor protein CD46, which is used as a cellular receptor of measles virus strains, was 
fused to the C4BP core domain. The fusion protein was produced as oligomers with eukaryotic 
293EBNA cells and showed significantly improved inhibition of virus binding to CD46 than the 
monomeric soluble CD46 in vitro.72 Moreover, it protected CD46 transgenic mice from a lethal 
measles virus infection in vivo.72 Further, a CD4-C4BP fusion protein produced by modified 293 cells 
showed an elongated plasma half-life in mice and appeared a better in vitro inhibitor of HIV infection 
than the monomeric soluble CD4.73  
 
2.6. The C-terminal oligomerization domain of the C4BP α chain as an adjuvant 
Interestingly, murine and chicken C4BP variants (IMX108 and IMX313, respectively) have been 
investigated as “molecular adjuvants” when fused with antigens for the vaccination against malaria 
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and tuberculosis.74,75 Since highly purified protein antigens are supposed to be poor immunogens, 
Ogun et al. investigated the applicability of antigen-C4BP fusion proteins to the immunization of mice 
against malaria using a series of C4BP homologues (murine, chicken and human).74 Thus, the weak 
antigen merozoite surface protein 1 (MSP119, 19 kDa) from Plasmodium yoelii was fused to the C4BP 
variants and applied for the vaccination of mice against the parasite challenge.74 It was found that all 
C4BP variants acted as adjuvants for the fused MSP119. The murine MSP119-C4BP fusion induced 
protective immunity in mice against a lethal parasite challenge but also induced antibodies against the 
murine C4BP.74 The use of a modified chicken C4BP variant (IMX313), distinct from the murine and 
human C4BP (less than 20 % amino acid identity to human C4BP), prevented the induction of 
antibodies against murine C4BP.74 When the Mycobacterium tuberculosis antigen 85A was fused to 
IMX313, a quantitative enhancement in the immune response in mice and in rhesus macaques was 
achieved.75  
 
2.7. PhaC bioparticles for the multivalent display of functional molecules 
The scaffolds described above are well-defined structures allowing for the multivalent presentation of 
fusion partners. Furthermore, other compounds can be applied for the multivalent display of functional 
molecules, among them viral- or nanoparticles, and cellulose.76-78 It has recently been shown that 
crystalline cellulose can be functionalized with sortase A recognition sites for enzyme-mediated 
conjugation of functional probes equipped with the corresponding tag.76  
Additionally, polyhydroxyalkanoate (PHA) beads have been applied for the immobilization and 
multivalent display of functional molecules such as enzymes and mycobacterial or viral antigens.79-81 
PHA is a carbon depository generated by several bacteria like Ralstonia eutropha. These polyesters 
can be synthesized with different short chain-length and accumulate as water insoluble granules inside 
the cells. The enzymes PhaA, PhaB and PhaC are involved in the synthesis of the short chain polyester 
polyhydroxybutyrate. The building block acetyl-CoA is condensed to acetoacetyl-CoA by the enzyme 
β-ketothiolase (PhaA), acetoacetyl-CoA is then reduced to (R)-3-hydroxybutyryl-CoA by the 
acetoacetyl-CoA reductase (PhaB), which in the last step is polymerized to PHA under catalysis of the 
PHA synthase (PhaC).81 Due to the fact that the PHA synthase remains covalently bound to the 
polyester, several PhaC fusion proteins were generated to functionalize the PHA beads.81 The 
proteinaceous fusion partners are displayed on the surface of the hydrophobic PHA particles facing the 
aqueous environment.81  
High-level expression of a PhaC fusion with a charged α-helical Ecoil domain resulted in the 
formation of bioparticles solely composed of PHA synthase, which displayed the coil domain on their 
surface.82 These inclusion body particles were generated in the absence of PhaA and PhaB and can be 
utilized for the multivalent display of molecules fused to a positively charged α-helical Kcoil 
domain.82 Thus, paving the way for the immobilization of multienzyme cascades on the surface of 
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bioparticles. Cost effective particles equipped with enzyme cascades could be useful tools for multiple 
biotechnological in vitro processes and have been a focus of this work. 
 
2.8. Site-specific protein conjugation 
In addition to the direct fusion of functional molecules to scaffolds or antibodies, site-specific protein 
conjugation techniques have become a powerful tool, especially considering antibody-drug conjugates 
(ADCs).83 Site-specific protein modifications allow for the attachment of various molecules of 
different nature, among them fluorophores, toxins, or synthetic peptides, to the defined positions 
within proteins in a modular fashion. Several chemical and enzymatic approaches have been developed 
over the recent years to extend the toolbox of protein modifications. Chemical linkage to lysine or 
cysteine residues using activated esters (e.g. NHS) and maleimide-functionalized probes, respectively, 
has been widely applied to generate more or less heterogenous conjugates, such as food and drug 
administration (FDA) approved ADCs Adcetris and Kadcyla.84 To generate homogenous conjugation 
products, site-specific strategies were established which rely on the catalytic function of enzymes 
recognizing specific peptide tags which need to be introduced into the protein of interest. As an 
example, microbial transglutaminases (mTGs) recognize glutamines within certain peptide sequences 
(e.g. LLQG) and mediate the formation of an isopeptide bond between the glutamine residue and a 
primary amine of a lysine under the release of ammonia.85,86 This way primary amine -containing 
probes can be selectively ligated to glutamine residues in target proteins. Another example for an 
enzyme that can be applied for site-specific protein modification is Sortase A. 
 
2.8.1. Sortase A 
 
Sortase A (SrtA) is a transpeptidase found at the plasma membrane of Staphylococcus aureus and 
other Gram-positive bacteria. SrtA from S. aureus is a calcium-dependent type II membrane protein 
that mediates the ligation of surface polypeptides with an LPXTG tag to an oligoglycine residue of the 
cell-walls peptidoglycan. The N-terminal membrane anchor can be removed for the recombinant 
production of soluble SrtA in E. coli cells.87 The enzyme recognizes an LPXTG motif, and the active-
site cysteine (Cys184) mediates the cleavage of the amide bond between the threonine and the glycine, 
which results in a covalent acyl-enzyme intermediate (Figure 8).88 An amino group of an oligoglycine 
probe can then attack the carboxylic group of the threonine at the thioester intermediate, which results 
in the ligated product.88 A water molecule can also hydrolyze the acyl-enzyme intermediate.  
The active-site cysteine of SrtA was exchanged with an alanine residue to resolve the crystal structure 
of SrtA with the bound recognition sequence LPETG.89 The structure revealed that the LPETG motif is 
held in position by hydrophobic interactions of its leucine and proline residues with SrtA, while the 
peptide bond connecting threonine and glycine is located between the active-site Cys184Ala and the 
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Arg197 residue.89 Further, the conserved His120 residue is essential for SrtA activity and it is 
suggested that it forms a thiolate-imidazolium pair with Cys184 for the catalysis of the 
transpeptidation.90 It has been suggested that Cys184 and His120 are reverse protonated and that the 
Cys184 thiolate attacks the carbonyl of the Thr-Gly bond, which generates a tetrahedral oxyanion 
transition intermediate.91 The nitrogen of the glycine leaving group is then protonated by His120, 
which leads to the acyl-enzyme thioester.88,91 His120 could then deprotonate the N-terminal amine of 
an oligogylcine that attacks the acyl-enzyme thioester as a nucleophile generating a tetrahedral state.91 
This intermediate state can be protonated, producing the transpeptidation product and regenerating the 
active site.91 A calcium ion is supposed to stabilize the substrate binding site of SrtA from S. aureus.  
Interestingly, a calcium-independent SrtA mutant was also generated by the substitution of two 
glutamine residues (E105K/E108A).92,93  
Due to the relatively short recognition sequences SrtA has been widely used for a plethora of 
conjugation reactions and has been in the focus of multiple mutagenesis studies. The group of David 
Liu developed a yeast surface display method for the screening of Sortases with altered functionalities. 
They were able to isolate a SrtA mutant with a 140-fold increase in LPETG-coupling activity (kcat / Km 
LPETG) and a 3-fold improved turnover (kcat) compared to the wildtype.94 The best isolated variant 
contained 4 mutations (P94S, D160N, D165A, K196T) resulting in a 50-fold decrease in Km towards 
 
Figure 8: (A) Sortase A reaction scheme. A probe (blue) carrying the LPXTG recognition sequence and an oligoglycine 
tagged functional probe (green) are incubated with Sortase A. Sortase A cleaves off all residues C-terminal of the threonine 
residue with its active-site cysteine (Cys184) resulting in the covalently linked acyl-enzyme intermediate. The amine of the 
oligoglycine tagged probe acts as a nucleophile and attacks the carboxylic group of threonine, yielding the the ligated 
product. (B) Sortase A (Cys184Ala) crystal structure with LPETG ligand (PDB-ID: 1T2W). The LPETG ligand is depicted 
with yellow cylinders. Residues Glu105 and Glu108 of the calcium-binding site are labeled.  
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the LPETG substrate compared to the wildtype enzyme.94 However, due to a 40-fold increase in Km for 
the GGG substrate, a pentamutant (P94R/D160N/D165A/K190E/K196T) was generated with a 1.8-
fold improved affinity towards the GGG substrate compared to the tetramutant and a 3.6-fold 
enhanced turnover (kcat) compared to the wildtype.94 In a follow-up study, the researchers aimed at 
changing the substrate specificity of SrtA variants for the orthogonal application of two SrtA variants 
to protein labeling.95 The isolated variants eSrtA (4S9) and eSrtA (2A9) specifically recognize two 
different tags, LPESG and LAETG, respectively, hence enabling the orthogonal conjugation of two 
different substrates to a single protein.95 Due to their high efficacy for protein labeling, the evolved 
pentamutant named eSrtA (Mut5) and the variants eSrtA (4S9) and eSrtA (2A9) were applied for 
SrtA-mediated conjugations throughout this work. 
 
2.9. Target proteins 
Antigen binding molecules such as monoclonal antibodies and other formats as described above have 
found to be effective therapeutics for the treatment of cancer. Due to the fact that certain cancer cells 
overexpress particular receptors, e.g. the growth factor ones, on their surface, they can be 
discriminated from healthy cells and tissues. Using highly specific antibodies, cancer cells can be 
specifically bound and, depending on the mode of action of the antibody molecules, eliminated from 
the body. Another strategy is the capturing of free ligands, i.e. growth factors, from the blood stream to 
inhibit the growth of tumor cells. Furthermore, blocking of immune checkpoint receptors that 
downregulate immune responses against tumors has emerged as an interesting approach.96 Diverse 
tumor-relevant target proteins have been identified to this date. The tumor-related proteins that were 
addressed in this work are briefly described in the following. 
 
2.9.1. Death Receptor 5 
Programmed cell death, also referred to as apoptosis, is a permanent process in the human body 
responsible for the elimination of aging cells, e.g. old skin or liver cells, cells with DNA damages, as 
well as self-reactive lymphocytes. During the process of cell suicide, morphologic changes like 
reduction of cell volume, nuclear fragmentation, chromatin condensation and organelle disruption 
occur.97 On the molecular level, cysteine aspartyl-specific proteases (caspases) are activated, proteins 
and DNA are disassembled and the cell membrane is altered in a way that apoptotic cells are labeled 
for phagocytosis.97 The so-called apoptotic cascade is induced by both internal and external signals. 
DNA damage and cell distress are internal signals that activate pro-apoptotic members of the BCL2 
gene superfamily and further lead to the mitochondrial release of apoptogenic factors into the 
cytosol.98-103 As a response, apoptosis initiating protease caspase-9 is recruited and activated by the 
apoptosome complex. In addition, caspase-9 activates executioner proteases caspase-3, -6 and -
7.98,101,104 External signals bind to death receptors on the cell surface and initiate apoptosis by its 
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oligomerization. Engaging of death receptors and their intracellular death domains leads to the 
formation of the death-inducing signaling complex (DISC), which is composed of the Fas-associated 
death domain protein (FADD) and procaspases-8 and -10. Activation of caspase-8 and -10 initiates 
apoptosis by activating executioner caspases-3, -6 and -7 (Figure 9).  
One of these external signals, the tumor 
necrosis factor (TNFα) related apoptosis 
inducing ligand (TRAIL), was found to induce 
apoptosis in a set of tumor cells by binding to 
the cell-surface death receptors, namely death 
receptor 4 and 5 (DR4; DR5) also called TRAIL 
receptor 1 and 2 (TRAIL-R1 & TRAIL-R2). 
TRAIL is a type II transmembrane protein that 
forms a homotrimer and, upon ligation of its 
cell-surface death receptors, apoptotic signaling 
is transduced. Despite of DR4 and DR5, which 
signal apoptosis by their death domain, TRAIL 
additionally binds to three decoy receptors, 
namely DcR1, DcR2 and osteoprotegrin (OPG), 
which do not induce apoptosis (Figure 9).105-110 
The cytokine TRAIL specifically induces 
apoptosis in a variety of tumor cells while 
sparing normal cells and tissues.111-114 Non-
cancerous cells express decoy receptors on their 
surface, which lack a functional death domain 
to induce apoptotic signaling.115 This property 
makes TRAIL and its receptors interesting and 
promising candidates for cancer therapy. 
 
2.9.2.  Cytotoxic T Lymphocyte Antigen 4 
The cytotoxic T lymphocyte antigen 4 (CTLA-4) belongs to the CD28:B7 immunoglobulin 
superfamily and is a major negative regulator of peripheral T cell response.116,117 It is presented on the 
surface of effector T cells as well as on T regulatory (T reg) cells. Upon activation of naïve T cells by 
antigen-specific T cell receptor (TCR) crosslinkage and a co-stimulatory signal B7-CD28, CTLA-4 
presentation is induced.117 CTLA-4 then competes with CD28 for B7 binding, while CTLA-4 
possesses a higher affinity towards B7.116 Binding of B7 to CTLA-4 turns off responses of activated T 
cells and initiates T reg suppressive function.118 This fine-tuning of immune response makes CTLA-4 
 
Figure 9: Schematic illustration of the death receptor (DR4 
and DR5) and decoy receptor (DcR1, DcR2 and OPG) 
distribution pattern on cancer cells (left) and on normal and 
premalignant cells (right). While normal cells express high 
levels of decoy receptors and low levels of death receptors, 
cancerous cells show an opposite expression pattern. In 
addition to the higher expression level of decoy receptors 
lacking an intracellular death domain, normal cells express 
the inhibitory protein FLIP, that blocks the recruitment and 
activation of procaspase-8 and -10. (Inspired by Wu and 
Lippman 2011).  
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an important immune checkpoint receptor. Tumors evade elimination by T cells by interacting with 
immune checkpoint receptors like CTLA-4, which downregulate T cell response and lead to adaptive 
tolerance.96 Thus, antibodies blocking CTLA-4 interaction with its ligands were generated to enhance 
immune response against diverse tumors. Ipilimumab, a CTLA-4-blocking antibody developed by 
Bristol-Myers Squibb, showed a significantly prolonged survival of patients with advanced melanoma 
in a clinical trial.117 In 2011, the FDA approved the fully-human monoclonal antibody Ipilimumab for 
the treatment of metastatic melanoma. After treatment with CTLA-4-blocking antibodies, a higher 
portion of CD4+ and CD8+ effector T cells than FoxP3+ T reg cells was found in tumor infiltrates.116 
Cytotoxic CD8+ T cells were found to be essential for a therapeutic effect of CTLA-4-blocking 
antibodies, indicating killing of tumor cells by CD8+ effector T cells.116 Since T reg cells showed the 
highest expression level of CTLA-4, it has been recently found that not only the blocking of B7-
CTLA-4 interaction is responsible for the therapeutic effect of these antibodies, but also the reduction 
of T reg cells inside of tumors by ADCC.116 
 
2.10. Objectives 
Guided by evident progress in modern diagnostic and therapeutic methods, the field of novel, non-
conventional functional binding modules is growing rapidly. Possessing high affinity and specificity to 
their target molecules, such monovalent binders often suffer from unfavorable features, i.e. fast blood 
clearance and low target-retention times.20 However, their engineering towards a multivalent format 
allows to overcome this handicap, leading to an enhanced functional affinity, decreased dissociation 
from targeted tissues as well as to an improved biodistribution.20 Furthermore, multimerization reduces 
glomerular filtration and prolongs circulation due to the enlarged molecular mass and size. Depending 
on the target and the mode of action, oligovalency can be of peculiar advantage, as in the case of signal 
transduction by receptor crosslinking (i.e. signal leading to apoptosis). Moreover, the similar principle 
can be of interest not only for biomedical applications but for certain biotechnological processes, e.g. 
engineering of multienzyme cascades. 
This work is focused on the development of viable strategies allowing for the multimerization of 
functional units towards tailoring of their functional properties. In the frame of this research, several 
multimerization domains have been engineered to enable their applicability as scaffolds for the 
multivalent display of functional molecules of peptidic nature. More precisely, the human Fc domain 
of IgG, the oligomerization domain of the human C4b binding protein and, finally, PhaC inclusion 
body particles were used as oligo/multimerization frameworks. Thus, the Fc and C4BP constructs were 
used as scaffolds for drug design, and PhaC inclusion bodies were applied as carriers for the 
immobilization of multienzyme cascades for coupled reactions which is of particular interest in certain 
biotechnological processes.  
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4.1. Generation of a functionalized scaffold towards cancer therapeutics 
 
Title: 
An apoptosis-inducing peptidic heptad that efficiently clusters death receptor 5 
Authors: 
Bernhard Valldorf, Heiko Fittler, Lukas Deweid, Aileen Ebenig, Stephan Dickgießer, Carolin 
Sellmann, Janine Becker J, Stefan Zielonka, Martin Empting, Olga Avrutina, Harald Kolmar  
 
Bibliographic Data: 
Angewandte Chemie International Edition 
Volume 55, Issue 16, Pages 5085–5089, April 11, 2016. DOI: 10.1002/anie.201511894. 
First published online: March 15, 2016. 
 
Graphical Abstract: 
A modular approach to generate 
death receptor 5 (DR5) binding 
constructs comprising multiple 
copies of DR5 targeting peptide 
(DR5TP) covalently bound to 
biomolecular scaffolds of peptidic 
nature is presented. Multivalent 
ligands are obtained that 
specifically induce an apoptotic 
cascade in cancer cells. The 
number and spatial orientation of 
the copies are decisive for their 
receptor activation ability. 
 
Contributions by B. Valldorf: 
 
• Performed crucial experiments (protein engineering, bioconjugation, cell assays) 
• Wrote the manuscript 
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International Edition: DOI: 10.1002/anie.201511894
An Apoptosis-Inducing Peptidic Heptad That Efficiently Clusters
Death Receptor 5
Bernhard Valldorf, Heiko Fittler, Lukas Deweid, Aileen Ebenig, Stephan Dickgiesser,
Carolin Sellmann, Janine Becker, Stefan Zielonka, Martin Empting, Olga Avrutina, and
Harald Kolmar*
Abstract: Multivalent ligands of death receptors hold partic-
ular promise as tumor cell-specific therapeutic agents because
they induce an apoptotic cascade in cancerous cells. Herein, we
present a modular approach to generate death receptor 5
(DR5) binding constructs comprising multiple copies of DR5
targeting peptide (DR5TP) covalently bound to biomolecular
scaffolds of peptidic nature. This strategy allows for efficient
oligomerization of synthetic DR5TP-derived peptides in
different spatial orientations using a set of enzyme-promoted
conjugations or recombinant production. Heptameric con-
structs based on a short (60–75 residues) scaffold of a C-
terminal oligomerization domain of human C4b binding
protein showed remarkable proapoptotic activity (EC50=
3 nm) when DR5TP was ligated to its carboxy terminus. Our
data support the notion that inter-ligand distance, relative
spatial orientation and copy number of receptor-binding
modules are key prerequisites for receptor activation and cell
killing.
Derived from Greek and meaning the falling off of leaves,
the term “apoptosis” signifies a programmed set of events
leading to cell death. In the human body, apoptosis is
responsible for the elimination of aged, damaged, or self-
reactive cells. This cell suicide can be induced by certain
molecular triggers, with DNA damage and cell distress being
internal signals that activate a pro-apoptotic cascade that
leads to the mitochondrial release of apoptogenic factors into
the cytosol.[1] As a result, the apoptosis-initiating protease
caspase-9 is recruited and activated by the apoptosome
complex, thus inducing a further cascade of executioner
proteases (caspase-3, -6, and -7), which culminates in cell
lysis.[1a,2]
Alternatively to intrinsic stimuli, external triggers initiate
apoptosis upon binding to the so-called death receptors (DR)
located on the cell surface, thus promoting their oligomeriza-
tion. This causes the formation of the death-inducing signal-
ing complex (DISC) and activation of caspase-8 and -10,
which actuate a cascade of executioner caspases. Among
these external agents, the tumor necrosis factor (TNFa)
related apoptosis-inducing ligand (TRAIL) is of major
importance as it promotes apoptosis in cancer cells upon
binding to the death receptors 4 and 5 (DR4 and DR5).
Native TRAIL is a type II transmembrane protein that
possesses an architecture of a homotrimer. It binds apoptosis
mediating DR4 and DR5, as well as three decoy receptors,
namely DcR1, DcR2, and osteoprotegrin (OPG), which do
not induce apoptosis.[3]
TRAIL specifically triggers apoptosis in tumor cells while
sparing healthy cells and tissues.[4] This makes TRAIL and its
receptors promising candidates for cancer therapy.
To date, several TRAIL-mimicking molecules and anti-
bodies directed against DR4 or, more often, DR5 have been
generated, among them several monoclonal antibodies.[5] To
gain cytotoxic activity at least in cell culture experiments,
these bivalent binders require a secondary cross-linking agent
that mediates antibody oligomerization in vitro.[6]
Soluble recombinant TRAIL and its DR4- or DR5-
specific engineered variants, as well as single-chain variable
antibody fragments (scFvs), multimerized camelid single
domain antibody domains (nanobodies), and several DR5-
targeting oligopeptides have been reported to date (Support-
ing Information, Table S4).[1a,7] Using recombinant screening,
a DR5-targeting peptide (DR5TP) was identified, which
competes with TRAIL upon binding to the receptor.[8] This
pentadecapeptide possesses an extended DR5 binding loop,
which is stabilized by a disulfide bond between two cysteines
(Scheme 1 and the Supporting Information).[8] Solitaire
DR5TP does not induce apoptosis in cancer cells even at
millimolar concentrations,[9] whereas its crosslinked bi- and
trivalent derivatives (Figure S1A–D) trigger this process in
DR5-positive cells.[9] Interestingly, the hexavalent adaman-
tane-based dendrons (Figure S1D) showed no improvement
of cytotoxic activity in cellular assays compared to the
trimeric adamantane counterpart (Figure S1B, Table S4).[10]
Herein, we report on DR5-specific constructs that induce
apoptosis in tumor cells (Scheme 1). We designed macro-
molecular architectures bearing multiple DR5 binding motifs
and assembled them using scaffold-assisted enzyme-pro-
moted conjugation (Scheme 2). As a binding moiety we
chose disulfide-linked DR5TP (Schemes 1 and 2) as this
peptide revealed no binding to DR4, DcR1, or DcR2.[9] In this
peptide, the N-terminal tryptophan, two residues within the
disulfide loop and the C-terminus are crucial for binding to
the receptor.[8]
[*] B. Valldorf, H. Fittler, L. Deweid, A. Ebenig, S. Dickgiesser,
C. Sellmann, J. Becker, S. Zielonka, Dr. O. Avrutina,
Prof. Dr. H. Kolmar
Clemens-Schçpf-Institut f¸r Organische Chemie und Biochemie
Technische Universit‰t Darmstadt
Alarich-Weiss-Strasse 4, 64287 Darmstadt (Germany)
E-mail: kolmar@biochemie-tud.de
Dr. M. Empting
Helmholtz Institute for Pharmacological Research Saarland (HIPS)
Universit‰tscampus E8 1, 66123 Saarbr¸cken (Germany)
Supporting information for this article can be found under:
http://dx.doi.org/10.1002/anie.201511894.
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The number of ligand copies was specified by the
biomolecular template taken for its oligomerization
(Scheme 2). First, we considered the Fc part of human IgG
(Scheme 2), which has been reported to serve as a scaffold for
di- and tetramerization of peptides.[11] This framework retains
desirable attributes of antibodies, that is, prolonged plasma
half-life and high apparent affinity due to its bivalent avidity.
Another candidate, a scaffold based on the a-chain of the C-
terminal oligomerization domain of human C4b binding
protein[12] (C4BP, Scheme 1 and 2), which is a plasma
component without biological function due to the lack of
complement control proteins (CCP),[13] allows assembly of
seven DR5TP units. This construct can be easily produced
recombinantly as a thioredoxin fusion along with spontaneous
formation of seven disulfide bridges, which yields a stable
heptavalent architecture (Section S1.4, Figure S4).[12] As an
additional advantage, conjugation with this scaffold that
consists of seven a-helical units, each comprising approx-
imately 60 residues, results in a significantly enhanced plasma
half-life of ligated molecules.[12,14]
Generally, the choice of an oligomerization scaffold is of
major significance as upon binding to DR5 valence and
spatial positioning of the ligand seems to play the key role for
efficient death signaling.[8–10] Thus, the selected biomolecular
frameworks, namely an Fc antibody domain 4 and C4BP
derivatives 5 and 6, were tailored for the decoration with two,
four, or seven copies of DR5TP-derived ligands 2 and 3
(Scheme 2). To localize the tethered binding units in the
target oligomers at defined positions, we introduced enzyme
recognition sites and attached DR5TP-based fragments by an
enzyme-catalyzed coupling (Scheme 2). For this purpose we
applied engineered sortases referred to as SrtA1-3 (Table S1),
which catalyze formation of an amide bond between glycine
and b-hydroxy-bearing amino acids (Ser, Thr) located,
respectively, at the N-terminal oligoglycine and the C-
terminal LXiEXiiG counterparts (Scheme 2, Figure S2).
[15]
The used sortases were tailored to recognize certain peptide
tags enabling modularity of ligand attachment (Section S1.6,
Figure S2, S3, and Table S2). Thus, the Fc scaffold 4 was
designed to carry two payloads either C- or N-terminally
(conjugates 9, 10, Figure 2, Table S3), and 4 payloads (two at
the C- and two at the N-terminus; construct 11, Figure S3).
The scaffold of C4BP was loaded with seven DR5-binding
motifs, either C- or N-terminally (constructs 5, 6, 12–15 ;
Figure 2, Table S3).
Tagged DR5-binding ligands (Scheme 2, Table S3) were
assembled by Fmoc-SPPS followed by disulfide bond forma-
tion (1–3, 7 and 8 ; Figure S9–S14, Table S3). To study the
influence of the anchoring position on the efficiency of
enzyme-catalyzed coupling and bioactivity, in peptides 7 and 8
conjugation tags were installed via the side chain of lysine
(Sections S1.5 and S4).
Scheme 1. Binding of DR5TP to DR5 on cancer cells. Left: Monovalent
DR5TP (sequence is indicated) is not able to induce apoptotic signal-
ing. Right: DR5TP attached to the C-terminus of C4BP binds to DR5 in
a heptavalent manner and induces apoptosis.
Scheme 2. Scaffolds used in this work. Top: Representation of bi- and
tetravalent Fc conjugates 9, 10, and 11 and heptads 12 and 14.
Bottom: Conjugation of synthetic DR5TP-based ligands 2 and 3 onto
scaffolds 4, 5, and 6 using sortase A-mediated ligation. For N-terminal
ligation tag1 is cleaved by TEV protease, liberating tag2, which is then
conjugated with peptide 3 under SrtA2 catalysis.
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! Covalent grafting onto scaffolds 4–6 lead to formation of
oligomeric constructs 9–15. Enzyme-promoted reactions were
monitored by SDS-PAGE (Figures S15–S18) and showed
quantitative conversion within 30 min at 22 8C for constructs
9–13 (Figures S15–S17). Conjugates were isolated by size-
exclusion chromatography. Multivalent constructs 9–13, 16,
and 17 as well as biotinylated monomer 1 were examined for
DR5 binding using enzyme-linked immunosorbent assay
(ELISA, Figure 1). In our hands, 1 bound DR5 with
a dissociation constant (Kd) of 240 nm (Figure 1A; reported
Kd of 129 nm was determined for the unlabeled peptide by
surface plasmon resonance).[9] Compared to 1, bivalent
conjugate 9 with peptide ligands located at the C-termini of
an antibody Fc fragment showed an almost 3-fold improved
affinity (Kd= 92 nm), while the binding capacity of its N-
terminal counterpart 10 was slightly decreased (Kd= 134 nm),
and the tetravalent conjugate 11 demonstrated comparable
affinity (Kd= 84 nm, Table 1, Figure S5).
With its Kd of 25 nm, conjugate 12 bearing seven copies of
peptide 2 which are located at the C-termini showed the
strongest potency upon binding to DR5 receptor (Figure 1,
Table 1). This construct along with the N-terminally function-
alized variant was also recombinantly produced inE. coli cells
resulting in genetically fused compounds 16 (C4BP-DR5TP)
and 17 (DR5TP-C4BP) (Figure S17).
A dissociation constant of 23.1 nm for 16 accords with that
observed for enzymatically ligated 12 (Table 1, Figure 1C). In
contrast, the N-terminally fused 17 exhibited strongly
impaired binding (Kd= 2.1 mm, Table 1) due to an unfavorable
orientation of ligands. Accordingly, in the case when a sortase
tag was connected with the binding motif via the side chain of
an additional lysine (peptides 7 and 8), their conjugation with
scaffold 6 was hindered to a large extent and resulting
constructs 13 and 15 showed low or no affinity to DR5
receptor (Table 1). This indicates that the orientation of the
conjugated peptide plays a crucial role upon multivalent
binding.
The ability to induce apoptosis was
examined using colorectal cancer cell
line COLO205 (Figure 1). Even at the
concentration of 1000 mm no induction
of apoptosis was observed for mono-
valent 2. C4BP-based heptads bearing
fused or ligated DR5-binders at the C-
termini exhibited good cytotoxic activ-
ity (Figure 1D), while their N-terminal
counterparts did not induce apoptosis
(data not shown). Interestingly, recom-
binantly produced heptamer 16 was
more potent compared to the sortase-
conjugated heptad 12 (EC50 of 3 nm vs.
12 nm, respectively; Figure 1D). As
assumed, the conjugates that showed
impaired binding to DR5 (13, 14, 17)
did not induce apoptosis in vitro. Sur-
prisingly, no apoptotic signaling was
observed for the Fc-based bi- and
tetravalent DR5TP constructs (9–11)
even in the presence of cross-linking
agents (protein G and anti-Fc IgG, data
not shown). Compound 12 that pos-
sessed, compared to the other hepta-
meric constructs, the closest arrange-
ment of its seven receptor-binding
peptides induced the strongest
response. In view of this finding it
is tempting to speculate that dense
multivalent local clustering of a DR5
targeting peptide is a prerequisite for efficient receptor ac-
tivation.
We additionally investigated the most potent heptad 16 in
an AnnexinV FACS assay, which allows for the discrimination
of apoptotic and necrotic cells (Figure 2A–D, Section S1.9).
Figure 1. ELISA binding studies and cytotoxicity assay. A) Binding of monovalent 1 to DR5
(Kd=240 nm). B) Binding of sortase A conjugated heptavalent construct 12 to DR5 (Kd=25 nm).
C) Binding of fusion protein 16 to DR5 (Kd=23 nm). D) Cytotoxic activity of 12 (EC50=12 nm)
and 16 (EC50=3 nm) on COLO205 cells (HEK293 cells were used as negative control).
Table 1: Binding affinity (Kd) towards DR5 and apoptotic potency (EC50)
of synthesized constructs.
Construct Conjugate Valence Kd [nm] EC50 [nm]
1 – 1 240 >1î106
9 Fc-DR5TP 2 92 >1400
10 DR5TP-Fc 2 133 >1000
11 DR5TP-Fc-DR5TP 4 84 >1150
12 C4BP-DR5TP 7 25 12
13 C4BP-DR5TP 7 1061 >500
14 DR5TP-C4BP 7 – >580
15 DR5TP-C4BP 7 – n.d.
16 C4BP-DR5TP 7 23 3
17 DR5TP-C4BP 7 2100 >4000
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We found that in presence of 16 40% of the examined cells
underwent apoptosis after 2 h (Figure 2C), and after 3 h the
portion of apoptotic cells reached 70% (Figure 2D). How-
ever, it required higher concentration of DR5-binding agent
compared to the natural ligand TRAIL (Figure S6).
To conclude, heptavalent constructs 12 and 16 efficiently
induced apoptosis without a secondary antibody often
required to crosslink DR5- or DR4-specific antibodies.[6] To
the best of our knowledge, for the first time oligomerization
on recombinant scaffolds improved the cytotoxic activity of
DR5TP. Our data indicate that crosslinking of DR5 strongly
depends on the orientation and spatial organization of the
ligands on the scaffold. We show that C4BP could be used as
a platform of human origin to oligomerize target-binding
peptides in a modular way using an efficient enzymatic
approach. Additionally, we demonstrated that the most
potent candidates can be easily produced recombinantly
without sacrificing activity. This ranges the C4BP-based
symmetric, compact and stable multivalent scaffolds as
viable platforms for the enhancement of bioactivity of small
binders, especially when multiple valence is of peculiar
interest (as in the case of targets inducing apoptosis upon
crosslinking of the receptors, that is, DR4 and DR5). For
additional experiments with C4BP-fused alternative DR5
binders, see Figure S8.
Recently, apoptosis-inducing oligomeric DR5-targeting
nanobodies were developed (EC50 at the subpicomolar range;
Table S4).[7b] However, their clinical study was terminated due
to unexpected liver toxicity.[16] Several factors might have
contributed to this effect, among them immunogenicity and
induction of DR5 expression on hepatocytes due to the
particularly high potency of the nanobody leading to an
undesired activation of hepatocyte apoptosis.[7b,16] These
findings indicate that fine-tuning of potency and immunoge-
nicity requires special consideration upon the design of next-
generation apoptosis-inducing compounds. It will be interest-
ing to elucidate whether our modular approachmay open new
avenues for the development of potent and safe modulators of
tumor growth.
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Cystine-knot peptides targeting cancer-
relevant human cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4)
Franziska Maaß,a§ Joycelyn Wüstehube-Lausch,b§ Stephan Dickgießer,a§
Bernhard Valldorf,a§ Michael Reinwarth,a Hans-Ulrich Schmoldt,b
Matin Daneschdar,b Olga Avrutina,a Ugur Sahinb and Harald Kolmara*
Cystine-knot peptides sharing a common fold but displaying a notably large diversity within the primary structure of flanking
loops have shown great potential as scaffolds for the development of therapeutic and diagnostic agents. In this study, we dem-
onstrated that the cystine-knot peptide MCoTI-II, a trypsin inhibitor from Momordica cochinchinensis, can be engineered to
bind to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), an inhibitory receptor expressed by T lymphocytes, that has
emerged as a target for the treatment of metastatic melanoma. Directed evolution was used to convert a cystine-knot trypsin
inhibitor into a CTLA-4 binder by screening a library of variants using yeast surface display. A set of cystine-knot peptides
possessing dissociation constants in the micromolar range was obtained; the most potent variant was synthesized chemically.
Successive conjugation with neutravidin, fusion to antibody Fc domain or the oligomerization domain of C4b binding protein
resulted in oligovalent variants that possessed enhanced (up to 400-fold) dissociation constants in the nanomolar range. Our
data indicate that display of multiple knottin peptides on an oligomeric scaffold protein is a valid strategy to improve their
functional affinity with ramifications for applications in diagnostics and therapy. Copyright © 2015 European Peptide Society
and John Wiley & Sons, Ltd.
Additional supporting information may be found in the online version of this article at the publisher’s web site.
Keywords: cystine-knot peptides; avidity; CTLA-4; combinatorial screening; peptide oligomerization
Introduction
In recent years, cystine-knot peptides (often named knottins or
miniproteins) emerged as a promising class of biomolecules with
certain characteristics thatmake them particularly attractive for var-
ious diagnostic and therapeutic applications. These miniproteins
are small (around 30 amino acids) peptidic molecules with a well-
defined three-dimensional structure comprising three disulfide
bonds (CysI-CysIV, CysII-CysV, CysIII-CysVI) [1,2] that form a pseudo-
knotted structural scaffold. Because of this unique architecture,
knottins exhibit an extraordinary thermal, proteolytic, and chemical
stability [3,4]. These peptides are easily accessible by recombinant
and chemical synthesis [5], and their loops are variable for ex-
change and insertion of amino acids without the loss of structure
and function [6,7]. Combined with their potential for oral delivery
[8,9], knottins have attracted considerable interest as frameworks
for pharma-inspired peptide engineering [10–12].
Cystine-knot peptides with desired binding characteristics have
been obtained by rational design and via combinatorial library
screening. For example, potent inhibitors of human matriptase-1
with inhibition constants in the low nanomolar to subnanomolar
range were recently generated via screening of combinatorial li-
braries by yeast surface display [13]. Further, screening of combina-
torial libraries derived from the cystine-knot scaffold of kalata B1
cyclotide was used to gain peptides that antagonize the growth
factor receptors neuropilin-1 and neuropilin-2 epitopes involved
in the antagonism of vascular endothelial growth factor [14]. Using
various cystine-knot peptides as a framework for engineering,
Cochran and coworkers isolated potent binders of different
integrins that were particularly useful for tumor imaging because
the radiolabeled or fluorescently labeled knottins were shown to
selectively target murine tumors [15–18]. Recently, the cyclic pep-
tide MCoTI-I [19] has been designed to efficiently antagonize intra-
cellular p53 degradation. The resulting cyclotide combined high
stability in human serum with pronounced cytotoxicity because
of the activation of the p53 tumor suppressor pathway in tumor
cells, thus inhibiting tumor growth in a xenograft model [20]. A
synthetic cystine-knot peptide Ziconotide derived from a cone
snail toxin was approved by both the US Food and Drug Adminis-
tration (FDA) and European Commision as an analgesic agent and
is currently on the market under the brand name Prialt [21].
Knottins were also engineered towards improved oral availability
[8,9,22–24].
* Correspondence to: Harald Kolmar, Institute of Organic Chemistry and
Biochemistry, Technische Universität Darmstadt, Alarich-Weiss-Str. 4, 64287
Darmstadt, Germany. E-mail: Kolmar@Biochemie-TUD.de
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Darmstadt, Darmstadt, Germany
b BioNTech AG, Mainz, Germany
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Multivalent interactions of biological molecules play an impor-
tant role in living systems. A multivalent ligand comprises multiple
copies of respective monomers conjugated in a certain manner,
thus allowing for their simultaneous binding tomultiple target mol-
ecules located, e.g. on the surface of cells. Many research groups
have successfully generated multivalent ligands to increase the
net binding affinity and specificity of the ligand to the receptor
[25,26]. Direct peptide oligomerization or polymeric display of pep-
tides on an oligomeric scaffold was successfully used to enhance
the functional affinity of binding molecules to their targets because
of an avidity effect [27–30]. This strategy was also applied to the
binding peptides with cystine-knot architecture. Thus, chemical
dimerization of a knottin that recognized the thrombopoietin
receptor resulted in the conversion of a receptor antagonist into
an agonist [31]. However, to the best of our knowledge, to date,
no systematic study has been reported for cystine-knot peptides
aimed at improving their functional affinity by scaffold-mediated
oligomerization, which implies diverse protein scaffolds and results
in different geometry and copy numbers.
In this work, we studied the avidity effects of knottin bindingwhen
displayed on oligomeric domains using a peptidemonomerwith low
specific affinity to human cytotoxic T lymphocyte-associated antigen
4 (CTLA-4, CD152). CTLA-4 plays an important role in the natural im-
mune response and is expressed on the surface of T cells as a dimer
after their activation [32,33]. Because of its negative regulation of
the immune response [34–36], CTLA-4 became an attractive target
for immunotherapy of cancer [37–39] and other diseases [40–42].
CTLA-4 signaling results in down-regulation of T cell function and
inhibition of activated T cell expansion. Upon immunization with a
non-stimulatory antibody against CTLA-4,mice showed an enhanced
resistance to tumor challenge andwere evenable to clear established
tumors [37]. An anti-CTLA-4 monoclonal antibody, Ipilimumab, is
FDA-approved for the treatmentofmelanomasince2011 [43].Herein,
we report the development of engineered, selective CTLA-4 binders
based on cystine-knot peptide oMcoTI-II, the acyclic derivative of
the protease inhibitor MCoTI-II from Momordica cochinchinensis
[44,45]. The avidity effects of various dimeric, tetrameric and
heptameric variants are discussed.
Materials and Methods
Library Cloning
A randomized library of gene variants based on the oMCoTI-II
framework was generated with pre-made codon mixtures [46].
The encoding gene pool was amplified using Taq polymerase and
primers with 50-bp overlap to the pCT yeast display plasmid up-
stream or downstream of the NheI and BamHI restriction sites
[47]. Subsequently, the polymerase chain reaction (PCR) product
was purified by phenol/chloroform extraction. The pCT vector was
digested with NheI and BamHI and purified using sucrose density
gradient centrifugation. Saccharomyces cerevisiae strain EBY100
was transformed with DNA insert (12μg) and linearized plasmid
(4μg) as described [48].
Flow Cytometry and Library Screening
The yeast library (approximately 3× 108 transformants) was grown
at 30 °C in selective media synthetic dextrose growth medium with
casamino acids (SD-CAA, 5.4 g/l Na2HPO4, 8.6g/l NaH2PO4 · H2O,
6.7g/l yeast nitrogen base without amino acids, 5 g/l Bacto
casamino acids, and 20g/l glucose) and induced to express
oMCoTI-II mutants on the yeast cell surface at 20 °C in selective
media containing galactose synthetic galactose growth medium
with casamino acids (SG-CAA). Expression level and CTLA4 binding
of yeast-displayed miniprotein variants were determined by flow
cytometry. Therefore, 1 : 20 dilutions of anti-cMyc antibody (mono-
clonal, mouse, Abcam; Cambridge, UK), anti-mouse IgG biotin-
conjugate (polyclonal, goat, Sigma–Aldrich; St. Louis, MO, USA),
and Streptavidin-R-phycoerythrin (SPE)-conjugate (Invitrogen)
were added consecutively to 1× 107 cells for 10min on ice.
For the first selection round, approximately 6×108 cells were an-
alyzed for binding to CTLA-4-Ig (Abatacept/Orencia®, Bristol Myers
Squibb; New York City, NY, USA). A two-color fluorescence activated
cell sorting (FACS) was used to select for cell surface presentation
and target binding. Therefore, 1× 108 cells were incubated consec-
utively with fluorescein-labeled 1μM CTLA-4-Ig for 30min on ice
and with 1 : 20 dilutions of mouse monoclonal anti-cMyc antibody,
anti-mouse IgG biotin conjugate, and streptavidin, R-phycoerythrin
conjugate (SPE) for 10min on ice, respectively. To ensure library
diversity, next screening rounds were performed with at least ten
times the number of yeast cells collected in the previous round.
Collected yeast cells were cultured after each screening round in
SD-CCA medium, induced for expression in SG-CCA medium, and
sorted by subsequent rounds of FACS to obtain an enriched popu-
lation of CTLA-4 binders (parameters: trigger side scatter 650,
FL1 600, and FL2 600). Labeling was altered in screening round
three. To this end, the cells were incubated consecutively with
1μM CTLA-4-Ig for 30min on ice and with 1 : 20 dilutions of anti-
human IgG phycoerythrin (PE)-conjugate (polyclonal, goat, eBio-
science; San Diego, CA, USA), anti-cMyc antibody, and anti-mouse
IgG-fluorescein conjugate (polyclonal, goat, Sigma–Aldrich) for
10min on ice.
Plasmid DNA from four isolated single clones of screening round
4 was recovered from yeast clones and transformed into DH5α
competent Escherichia coli cells for plasmid preparation. DNA
sequencing was performed by Seqlab (Göttingen, Germany).
Recombinant Production of Cystine-knot Peptides
The pools derived from the third and fourth yeast screening rounds
were subcloned into a pET-32a based expression vector (pET-32K)
to screen for CTLA-4 binding in a yeast-display independent setting.
In this plasmid, the peptide coding sequence is fused to His-tagged
thioredoxin separated by a thrombin protease cleavage site [49]. To
this end, the plasmid DNA was isolated from the yeast cells; the
miniprotein gene fragments were amplified via PCR and digested
with EheI and ApaI. Miniprotein gene pools were cloned into
NruI/ApaI digested expression vector pET32K and transferred into
E. coli SHuffle T7® (NEBiolabs). Single clones was cultured in 1ml ly-
sogeny broth (LB) medium supplemented with 100μg/ml ampicil-
lin and 0.4% (w/v) glucose at 37 °C using microwell plates. At an
optical density of ~0.8 at 600nm the cells were centrifuged and
suspended in fresh LB medium containing 100μg/ml ampicillin
and 1mM isopropyl-β-d-thiogalactopyranoside (IPTG) for induction
of protein expression that was performed overnight at 25 °C. Subse-
quently, cells were harvested by centrifugation, resuspended in
200μl lysis buffer [20mM Tris pH8.0, 2mM MgCl2, 20mM NaCl,
1mg/ml chicken egg white lysozyme (Merck, Darmstadt, Germany),
and 15U/ml benzonase nuclease (Merck)] and the cell suspension
was stored at !20 °C for at least 1 h. Cells were thawed afterwards,
incubated for 15min at room temperature and 10min at 80 °C. The
suspensions were centrifuged at 5000×g for 30min, and the super-
natant comprising soluble thioredoxin fusion proteins was used for
MAAß ET AL
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subsequent enzyme-linked immunosorbent assay (ELISA)-based
binding analysis.
Fusion proteins derived from 96-well expressions were
immobilized overnight in 50mM Na-carbonate buffer (pH9.4) on
wells of ELISA plates (MaxiSorp 96-well plates, Nunc; Rochester,
NY, USA). The plates were blockedwith 1% casein blocking solution
(Sigma) in TBS (150mM NaCl, 100mM Tris-HCl, and pH7.4) and sub-
sequently incubated with 250nM CTLA-4-Ig in TBS with 1% casein
for 1 h at 37 °C. Bound CTLA4-Ig was detected via an anti-human
IgG-horseradish peroxidase (HRP) conjugate (Sigma Aldrich) diluted
1 : 5000 in TBS with 1% casein. 3,3′,5,5′-tetramethylbenzidine (TMB,
Sigma Aldrich) was used as a chromogenic HRP substrate. After
10min incubation time at room temperature, the reaction was
stopped by the addition of 0.2 M HCl, and absorbance was mea-
sured at 450 nm in a Victor 3 V ELISA reader (Perkin Elmer, Waltham,
MA, USA).
Cloning of Expression Vectors for Fusion Proteins 4, 5, and 6
pEXPR-IBA42 (IBA BioTAGnology GmbH, Göttingen, Germany) with
sequences encoding a human Fc was received as a kind gift from
Christian Heinis, Lausanne, Switzerland. This vector contained an
ampicillin resistance gene, a cytomegalovirus (CMV) promoter, a
BM40 signal sequence for protein secretion, and an IgG1 Fc
fragment with Asn297Ala mutation (based on the nucleotide
sequence of human IgG1 heavy chain constant regions CH2 and
CH3; amino acids 236 to 446, Kabat numbering; accession number:
AAL96263). The hinge regionwas shortened to 12 residues with the
two cysteines replaced by serines [50].
The Fc fragment encoding sequence was PCR-amplified to intro-
duce ApaI and BamHI restriction sites at the 5′ and 3′ end of the Fc-
coding sequence, respectively, and cloned into pEXPR-IBA42 using
NheI and HindIII. The sequence encoding for peptide 1 was ampli-
fied by PCR and placed at the 3′ end of the Fc fragment coding re-
gion using the restriction sites BamHI and HindIII resulting in a
construct encoding for fusion protein 4. Likewise, the sequence
encoding for peptide 1 was placed at the 5′ terminus via NheI and
ApaI cloning leading to 5. Transfection-pure vectors were purified
by using PureYield Plasmid Midiprep System (Promega, Madison,
WI, USA).
For expression of the fusion protein 6, the peptide-coding se-
quence was amplified, digested with the restriction enzymes BglII
and NcoI, and ligated with pET32a-Trx-C4Bp [51] linearized with
the same restriction enzymes. Protein production and purification
were performed as described [51].
Peptide Synthesis and Biotinylation
The CTLA-4-binding cystine-knot peptide 2 was assembled on
RAM resin following the Fmoc strategy using a fully automated
microwave-assisted CEM Liberty peptide synthesizer. Aminotermi-
nal biotin coupling was achieved on-support using (+)-biotin upon
preactivation with 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluro-
nium hexafluorophosphate (HBTU) in the presence of diisopropyle-
thylamine (DIPEA). After acidolytic cleavage from the solid support,
oxidative folding was performed as described [52]. Reaction prog-
ress was monitored by analytical reverse phase high performance
liquid chromatography (RP-HPLC) and of liquid chromatography-
electrospray ionization-mass spectrometry (LC-ESI-MS), and the
folded peptide 2 was isolated from the reaction mixture by HPLC
upon completion of the reaction after 12 h (Fig. S1 in Electronic
Supplementary Information) [52].
Binding Studies Using Peptide 2
Affinity analysis was performed by ELISA. CTLA-4-Ig in PBS
(140mM NaCl, 10mM KCl, 6.4mM Na2HPO4, 2mM KH2PO4, pH7.4)
was immobilized on wells of an ELISA plate. To minimize nonspe-
cific binding, the plate was blocked with 3% bovine serum albu-
min (BSA) in PBS and subsequently incubated with biotinylated
peptide 2 in PBS with 1% BSA for 1 h. Bound miniprotein was
detected via ExtrAvidin-HRP-conjugate (Sigma–Aldrich), diluted
1 : 5000 in PBS with 1% BSA. TMB was used as chromogenic
HRP substrate. After 15-min incubation time at room temperature,
the reaction was stopped by the addition of diluted HCl, and
absorbance was measured at 450nm in an ELISA reader (GENios,
Tecan, Männedorf , Switzerland). The monoclonal antibody ce-
tuximab served as a control. For affinity measurement using
peptide-neutravidin conjugate 3, biotinylated cystine-knot pep-
tide 2 and neutravidin were mixed in a molar ratio of 4 : 1 and
incubated in 1% casein in PBS for 30min at room temperature.
The resulting construct 3 was immobilized on wells of an ELISA
plate. The plate was blocked with 3% casein in PBS and
subsequently incubated with CTLA-4-Ig in 1% casein in PBS for
1 h. Bound CTLA-4-Ig was detected via anti-hFc-HRP (Antikörper-
Online), diluted 1 : 5000 in PBS with 1% casein. TMB was used
as chromogenic HRP substrate.
Expression, Purification, and Affinity Titration of Fusion Pro-
teins 4, 5, and 6
Fusion proteins 4 and 5 were expressed in transiently transfected
HEK293-6E suspension cells. Cells were cultured in FreeStyle™ F17
Expression Medium (Life Technologies, Carlsbad, CA, USA) supple-
mented with 4mM l-glutamine (Sigma) and 50μg/mlG418 at
100 rpm shaking speed, 37 °C, and 5% CO2. Prior to transfection,
cells were resuspended in medium without antibiotics at a den-
sity of 2× 106 viable cells/ml overnight. For transfection 0.5μg
plasmid DNA per 1.7× 106 viable cells were preincubated
with 3μg 25 kDa linear polyethylenimine (Polysciences) for
15min and added to the cells. After 24h, tryptone was added
to a final concentration of 0.5%. After 5 days of expression,
cells were removed by centrifugation (10min, 4000 rpm) and
filtration (0.45μm). Fusion proteins 4 and 5 were purified using
protein A affinity column (1ml HiTrap Protein A HP column;
GE Healthcare, Uppsala, Sweden) and an Äkta FPLC purifier
system (GE Healthcare) and subsequently dialysed against PBS.
Protein production and purification of 6 were performed as de-
scribed [51].
For ELISA affinity titration, fusion proteins 4 and 5 were biotinyl-
ated using EZ-Link® Sulfo-NHS-LC-Biotin (Thermo Scientific, Wal-
tham, MA, USA) according to the manufacturers instructions and
afterwards purified by polyacrylamide spin desalting columns (7 K
MWCO, Thermo Scientific). Then CTLA-4-Ig in PBS was immobilized
on wells of an ELISA plate. The plate was blocked with 3% BSA in
PBS and subsequently incubated with biotinylated 4 and 5 in PBS
with 1% BSA for 1 h. Bound fusion proteins were detected upon in-
cubation with ExtrAvidin-HRP conjugate (Sigma Aldrich), diluted
1 : 5000 in PBS with 1% BSA. Binding of 6 to CTLA-4 was detected
with a mouse monoclonal anti-oligohistidine antibody (Qiagen) in
PBSwith 1%BSA followed by incubationwith anti-mouse IgG biotin
conjugate diluted 1 : 5000 in PBS with 1% BSA (Sigma Aldrich).
Bound fusion protein 6 was detected as described above using
ExtrAvidin-HRP conjugate; TMB was applied as a chromogenic
HRP substrate.
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Results
Library Design and Screening for CTLA-4 Binders
To obtain cystine-knot peptides that bind CTLA-4, a library based
on the trypsin inhibitor oMCoTI-II framework was generated upon
randomization of the inhibitor loop and neighboring residues
(Figure 1(A–C)). The inhibitor loop and the two CysI-preceding resi-
dues were exchanged against randomized amino acid sequences
having 6, 9, and 12 residues, respectively, to create peptide variants
with new molecular recognition properties. Previous studies with
the structurally similar miniprotein EETI-II showed high tolerance
of length and sequence diversity in non-conserved regions
[6,13,15]. A codon distribution with underrepresented hydrophobic
residues was chosen (Table 1). Because residues PGA (Figure 1(A))
may be of relevance for oMCoTI-II folding and stability, simulta-
neous full randomization was avoided by maintaining the original
residue at each position for 50% of the variants. Overall, the
randomization scheme applied here included 11 to 17 out of 34
to 40 residues.
The oMCoTI-II library-encoding DNA was genetically fused to the
S. cerevisiae Aga2p coding sequence. S. cerevisiae is a particularly
well-suited host for the synthesis of miniproteins because it
contains in the endoplasmic reticulum a set of folding helpers that
mediate disulfide bond formation together with a quality control
machinery to remove misfolded variants [53]. The resulting con-
structs are under control of the galactose promoter [54]. Induction
with galactose yielded a fusion protein comprising Aga2p, a
glycine-serine linker, an HA-epitope, the cystine-knot peptide, and
a cMyc epitope (Figure 2(A)). The fusion is covalently bound to
the surface-anchored Aga1p. The resulting miniprotein library
displayed a clonal diversity of 3× 108.
To select for the full-size miniprotein variants that are presented
on the yeast surface and show binding to CTLA-4, a two-color
staining and FACS procedure was performed (Figure 1(C) and
Figure 2(A)). In the initial sorting round, in total 6× 108 yeast cells
were labeled with 1μM CTLA4-Ig (a fusion protein consisting of
the extracellular domain of CTLA-4 and a human IgG Fc part) and
sorted by FACS to collect the 0.3% of yeast cells that displayed
the oMCoTI-II variants (detected through cMyc-antibody) and
showed the highest binding to fluorescein-labeled CTLA4-Ig
Figure 1. (A) Sequence and (B) structure of cystine-knot trypsin inhibitor oMCoTI-II (pdb: 1 ha9). Secondary structure is shown as cartoon, and cysteine
residues are depicted as yellow sticks. Cystine-forming residues are marked in the sequence in yellow, and the numbering of respective cysteines is
according to their appearance in the sequence. Randomized residues are color coded according to the residue distribution depicted in Table 1. (C)
Screening against human CTLA4-Ig. Fluorescence activated cell sorting histograms showing four rounds of sorting with constant target concentration
(1μM) for enrichment of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) binders. R1 to R4 denote the sorting round, and actual sorting gates are
shown. Display level (cMyc) is monitored by incubation with the antibodies anti-cMyc and anti-mouse-biotin followed by fluorescence labeling with
streptavidin, R-phycoeythrin conjugate (SPE). CTLA-4 binding is monitored by incubation with fluorescein-labeled CTLA-4-Ig. For details of two-color cell
staining, see Section on Methods and Ref. [13].
Table 1. Residue randomization of the oMCoTI library
Amino acids Residue randomization (%)
Red Blue Yellow Green
A 1.4 0.7 4.2 50
C 0.0 0.0 0.0 0
D 7.5 4.1 0.0 5
E 7.5 4.1 0.0 5
F 1.4 0.7 4.2 0
G 7.5 4.1 50 5
H 7.5 4.1 4.2 5
I 1.4 0.7 4.2 0
K 7.5 4.1 4.2 5
L 1.4 0.7 4.2 0
M 1.4 0.7 4.2 0
N 7.5 4.1 0.0 5
P 7.5 50 0.0 0
Q 7.5 4.1 0.0 5
R 7.5 4.1 4.2 5
S 7.5 4.1 0.0 5
T 7.5 4.1 4.2 5
V 1.4 0.7 4.2 0
W 1.4 0.7 4.2 0
Y 1.4 0.7 4.2 0
MAAß ET AL
wileyonlinelibrary.com/journal/jpepsci Copyright © 2015 European Peptide Society and John Wiley & Sons, Ltd. J. Pept. Sci. 2015; 21: 651–660
654
 
  Cumulative part   48
 
 
!
(Figure 1(C)). To exclude isolation of binders against streptavidin,
labeling was alternated for the third screening round from
fluorescein-bearing CTLA-4-Ig to CTLA-4-Ig detection using an
anti-human PE-conjugated antibody. After four screening rounds,
an enrichment of potential binding candidates was observed.
Binding of Monomeric Cystine-knot Peptides to CTLA-4
The pools from the third and fourth screening rounds were
subcloned into pET32K expression vector for expression as soluble
proteins in E. coli cells. Miniproteins from 224 randomly picked sin-
gle clones of the third round and 239 clones of the fourth screening
round were produced as fusions to thioredoxin [49] and subjected
to a qualitative ELISA analysis to examine CTLA-4 binding. While no
positive clones were obtained from the third screening round, sev-
eral putative CTLA-4 binders were identified from the fourth one
(Table 2); among them, peptide called MC-CT-010 (1) was pre-
sented 13 times, and the other nine sequences were unique.
To characterize the affinities and specificities of the engineered
oMCoTI-II peptides towards CTLA-4, four candidates (MC-CT-010
to MC-CT-040, Table 2) were expressed as thioredoxin fusions,
and an ELISA affinity titration was performed. In these experiments,
the chosen variants showed the respective apparent dissociation
constants of 3, 17, 7, and 20μM, approximately. The best candidate,
MC-CT-010 1, was assembled by Fmoc-SPPS (IBM, Armonk, NY, USA)
followed by biotinylation and oxidative folding resulting in the
biotinylated synthetic cystine-knot 2 (for the details, see Fig. S1 in
Electronic Supplementary Information). The binding constant of
the peptide 2 was estimated using ELISA. The analysis showed a
specific and concentration-dependent binding against human
CTLA-4-Ig and revealed a KD value of 3.7μM (Figure 2).
Oligomerization of Peptidic Monomers
To study a possible avidity upon binding to CTLA-4, which is a
dimer, the peptide monomers were oligomerized using diverse
oligovalent proteins as scaffolds. Thus, the tetramer of synthetic bi-
otinylated cystine-knot MC-CT-010 1 was generated through the
formation of a stable non-covalent complex 3 with the tetravalent
protein neutravidin (for numbering of the constructs, see Figure 4
upper row). This oligomer 3 showed a specific and concentration-
dependent binding to CTLA-4 and exhibited a KD in the nanomolar
range (Figure 3(A)).
Relying on these results, we designed several oligomeric archi-
tectures comprising the knottin monomer in different copies and
geometry (Figure 4). In these constructs, the cystine-knot counter-
part was genetically fused either to the C-terminus of a human
IgG1 Fc fragment or to the N-terminus and the C-terminus simulta-
neously. Because of the dimeric nature of an antibody Fc fragment,
it resulted in the formation of di- or tetramers of 1, namely, 4 and 5,
respectively (Figure 4). Following the expression in HEK293-6E cells
and purification by affinity chromatography, the dimer formation
Figure 2. Characterization of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)-binding peptide MC-CT-010 (1). (A) Schematic illustration of Aga1p/
Aga2p surface-displayed oMCoTI-II derived miniproteins (orange) flanked by the N-terminal HA (Human influenza hemagglutinin) epitope (blue) and the
C-terminal cMyc epitope (yellow). Display level (cMyc) is monitored by incubation with the antibodies anti-cMyc and anti-mouse-biotin followed by
fluorescence labeling with streptavidin, R-phycoeythrin conjugate (SPE, pink). Functional display of CTLA-4 binding of oMCoTI-II variants is monitored by
incubation with fluorescein-labeled CTLA-4-Ig (green). (B) Fluorescence activated cell sorting histograms for CTLA-4 binding of control cells and cells
displaying 1. Cells were labeled with 1μM CTLA4-Ig-FITC and cMyc-antibody. (C) ELISA for determination of the binding properties and specificity of 1. (D)
Enzyme-linked immunosorbent assay for determination of the binding affinity of 1. Error bars represent three independent measurements.
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was confirmed by gel filtration analysis (data not shown). Binding of
the resulting bivalent construct 4 to CTLA-4 was characterized with
a KD of 322nM, while the tetravalent variant 5 showed an even
higher affinity (KD of 118 nM, Figure 3(B.C), respectively).
To further increase the number of copies of binder 1, it was fused
to the small and compact scaffold of the oligomerization domain of
human C4BP, which is composed of seven covalently linked α-
helices to build a heptavalent architecture. Based on the recently
reported structure of this domain, we extended its pendant arms
N-terminally withmonomeric units of 1 [51]. The resulting construct
6 (having an additional N-terminal thioredoxin elongation that is
omitted at Figure 4 for clarity) was produced in E. coli cells as de-
scribed [51]. The binding studies revealed an apparent KD of
approximately 8 nM (Figure 3(D)) that was 445-fold lower compared
with the monomeric counterpart. None of the scaffold proteins
alone displayed nonspecific target binding (data not shown).
Discussion
In recent years, the engineering of knottins with desired binding
characteristics was mainly conducted by grafting peptides posses-
sing affinity towards a given target onto the rigid cystine-knot scaf-
fold via loop replacement [6,10,11,45,55]. An alternative strategy
that relies on high-throughput screening of combinatorial libraries
was also successfully applied to obtain knotted peptides that
Figure 3. Enzyme-linked immunosorbent assay (ELISA) affinity titration of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)-binding peptidic constructs
4, 5, 6. (A) ELISA for determination of the apparent binding affinity of neutravidin-coupled tetrameric construct 3. Plate was coated with 3 followed by
incubation with CTLA-4-Ig at different concentrations. (B–D) Affinity titration of divalent construct 4, tetravalent construct 5, and heptavalent construct 6,
respectively. Plates were coated with CTLA-4-Ig followed by incubation with the respective peptidic construct at different concentrations. Measurements
were done in triplicate.
Table 2. Sequence alignment of CTLA-4-binding MCoTI variants compared with wild type sequence. Cysteines I to VI are numbered according to the
appearance in the sequence. Region of randomized residues is colored. Gaps were inserted to superimpose the sequences because of different loop
lengths. The number of independent clones with identical sequences is indicated as abundance.
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address various targets, e.g. humanmatriptase, integrins, thrombin,
a tumor cell marker, or inhibitors of endothelial cell migration
[13,14,54,56,57]. In the present research, we isolated cystine-knot
peptides that bind to the extracellular domain of CTLA-4 from a
knowledge-based combinatorial library based on the cystine-knot
peptide McoTI-II. Miniproteins from M. cochinchinensis have been
extensively used as scaffolds to introduce novel biological activities
[13,20,22,23,58–61]. In this study, the functional loop of the trypsin
inhibitor oMcoTI-II and the neighboring residues were randomized,
as well as the second loop in spatial proximity to the inhibitor loop.
We recently applied a similar approach to the isolation of cystine-
rich miniproteins possessing inhibitory activity against matriptase
in the subnanomolar range. The same knottin scaffold, comparable
library size, and screening strategy were used [13]. However, de-
spite similar screening efforts, only low affinity binders of CTLA-4
(KD in micromolar range) were obtained in the present study. This
could be associated with the different interaction patterns. Indeed,
in the case of matriptase binding, a single exposed loop protrudes
into the cavity of the active site of the target protein and provides
both a geometrical match and the interaction enthalpy required
for tight binding. Possibly, lack of a concave interface on the surface
of CTLA-4, fitting to the conformationally constrained binding loop
of the miniprotein, may account for low-affinity binding. Neverthe-
less, we were able to isolate ten different CTLA-4-interacting
knottins (Table 2). It remains to be elucidated whether these vari-
ants with altered loop sequences address different sites on the sur-
face of the target protein.
Several concepts to improve receptor-ligand interaction have
been described in the literature. A few examples include affinity
maturation of a given binding protein by error-prone PCR, site sat-
uration mutagenesis or parsimonious mutagenesis [62–64]. Alter-
natively, protein oligomerization can be applied to induce avidity
effects. In simplistic terms, binding of a single monomer to a recep-
tor results in a transient increase of the local concentration of
neighboring coupled ligands, which may lead to cooperative
effects and enhanced binding. Particularly for target molecules that
reside on a solid or cell surface in large copy numbers, or which are
themselves dimers, as in the case of CTLA-4 [65], linkage of at least
two ligands into a single molecule may allow for simultaneous
binding ofmore than one receptor resulting in high-affinity interac-
tions [26]. In this work, we systematically investigated the effect
of peptide ligand oligomerization on its binding to CTLA-4. We
showed that binding efficacy depends on the number and density
of the displayed interacting entities, their spatial arrangement,
flexibility, and orientation (Figure 4).
Numerous oligomerization scaffolds have been to date applied
to enhance functional affinity, among them streptavidin for tetra-
merization [66–70], antibody Fc fragment for dimerization and
tetramerization [30,50,71–73], the core domain of C4b-binding pro-
tein for heptamerization [27,74], IgM for decamerization [71], or
viral particles for linking hundreds of ligands together [75,76]. In re-
cent years, streptavidin has been extensively used for this purpose
because it assembles into a stable tetramer that effectively binds to
each biotinylated ligand because of the extraordinary affinity of
biotin to streptavidin (KD= 10
!15
M). The resulting tetravalent com-
plex is stable over a wide pH range even at elevated temperatures
[67]. We observed a 23-fold enhancement of apparent affinity
of the neutravidin complex 3 (Figure 4) compared with the mono-
mer 2. In addition, staining of CTLA-4 expressing cells showed that
3 specifically recognized membrane-bound CTLA-4 and control
cells remained unstained (Fig. S1 in Electronic Supplementary
Information).
Recently, an interesting concept was introduced by Nunn and
coworkers, who generated heterodimers of peptides, which bind
to two distinct, non-competing epitopes on the target molecule.
To this end, two different biotinylated peptidic ligands obtained
by phage display library screening were mixed with streptavidin
at a 2 : 2 : 1 molar ratio. Some of the resulting heterooligomeric
mixed conjugates displayed strong synergistic effects with respect
to binding to a single target protein, most likely due to multivalent
interactions with the same target molecule [69,70]. It may be useful
to apply this strategy for enhancement of knottin binding tomono-
meric CTLA-4 by combinatorial testing of all possible 45 knottin
pairs of the ten different miniproteins with low affinity to CTLA-4
that were obtained from combinatorial library screening (Table 2).
The Fc-part of antibody IgG has been extensively used as a
multimerization scaffold, because it combines the advantages of
ligand oligomerization with strongly enhanced plasma half-life
due to FcRn-mediated antibody salvage [77,78]. Peptibodies, pep-
tides grafted onto an Fc domain, retained both desirable features
of antibodies, an increased apparent affinity conferred by the
dimerization of two Fc fragments and a long plasma residence time
[30]. Romiplostim, marketed under the brand name Nplate, is
the first peptibody to be approved by the FDA and the European
Medicines Agency (EMA) for the treatment of immune thrombocy-
topenic purpura. Several others are in advanced clinical trials, illus-
trating the versatility of this concept [26]. The peptidic moieties
of these peptide-Fc fusions contain at a maximum one disulfide
bond. On the other hand, folding and oxidation of cystine-knot
peptides containing a three-disulfide pattern may result in
Figure 4. Schematic outline of the oligomeric constructs. Calculated relative apparent dissociation constants were obtained by dividing the measured
apparent dissociation constants for the monomer 2 by that of each oligomeric variant.
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disulfide-scrambled products. It is particularly complicated when
fused to Fc, where two more cysteines that reside in the adjacent
hinge region may affect proper folding. As a safety catch, cysteines
in the Fc hinge region were replaced by serines. Additionally, the
hinge regionwas shortened to a length of 12 amino acids, as shown
in another study with cysteine-rich peptides displayed on Fc [50].
Gel filtration analysis confirmed that this Fc construct lacking inter-
molecular disulfides still formed homodimers, mainly because of
hydrophobic interactions of the CH3 domains [79,80]. Recently, it
has been shown that a derivative of the cystine-knot peptide
EETI-II (engineered for integrin binding and used for tumor imag-
ing) was directly fused to the Fc region of mouse IgG2a without
removal of hinge region cysteines. In this construct, the ability for
tumor imaging was retained, which indicates that presence of
hinge region cysteines may not negatively interfere with formation
of the three disulfides in the grafted knottin peptide. No data on the
improvement of apparent affinity were reported in this paper [17].
We found that efficacy of the CTLA-4 binding was improved 11-fold
for the dimer 4 and 31-fold for the tetravalent variant 5 compared
with the parent peptide 1 (Figure 4).
It is difficult to assess the extent of possible disulfide scram-
bling in the CTLA-4 binding miniprotein when fused to Fc. To
investigate, whether MCoTI-II derived miniproteins have the gen-
eral capability to form the correct disulfide pattern upon recombi-
nant expression as fusion protein, we constructed an Fc fusion of
an acyclic MCoTI-II-based trypsin inhibitor miniprotein (Fig. S1 in
Electronic Supplementary Information) that shares with peptide 1
the same cystine-knot framework. For that miniprotein, it is known
that only the particular disulfide pattern, CI-CIV, CII-CV, CIII-CVI,
mediates biological activity, i.e. inhibition of trypsin-like protease
[81]. Thus, the inhibitory activity of the synthetic miniprotein with
defined cystine-knot topology was compared with that of the
recombinantly produced fusion protein bearing the same mini-
protein counterpart (Fig. S1 in Electronic Supplementary Informa-
tion). Comparable inhibition constants imply that a significant
fraction of the oMCoTI-II-based CTLA-4-binding miniprotein 1 in
fusion proteins 4, 5, and 6 very likely has the canonical cystine-
knot architecture (Fig. S1 in Electronic Supplementary Information).
An over 400-fold improvement of apparent affinity was observed
upon miniprotein fusion to the C4BP core domain. The crystal
structure of the human C4BP oligomerization domain revealed a
symmetric heptamer, which because of its small size of only 57 res-
idues per a monomer unit allows for the display of up to seven
fused ligands, positioned in close proximity to each other on the
donut-like nanoscaffold [51]. This domain was used recently for
the multivalent display of the HIV-1 fusion inhibitory peptide C46
and of two peptides that inhibited IgG binding to human factor VIII
[27,74]. Both constructs displayed prolonged in vivo half-life relative
to synthetic peptides, but only the mimotope peptides grafted
onto the C4bpα domain displayed a 20-fold enhancement of bind-
ing potency. This finding corroborates the notion that the extent of
binding improvement through multivalency cannot be predicted
quantitatively and requires systematic experimental evaluation of
each individual ligand-receptor pair.
In conclusion, we have converted a cystine-knot protease inhibi-
tor into a receptor binder bymolecular engineering and significantly
enhanced its binding to the dimeric target through oligomerization.
The resulting oligovalent conjugates bind the extracellular domain
of CTLA-4 with dissociation constants in the low nanomolar range.
It remains to be elucidated, whether these oligomers retain en-
hanced affinity in experiments with CTLA-4 overexpressing cells
and whether these constructs are able to alleviate the inhibitory
signaling between CTLA-4 and its receptor B-7. Moreover, recent
data indicated that the activity of anti–CTLA-4 antibody is mediated
at least in part via selective depletion of T regulatory cells within tu-
mor lesions, which is dependent on the presence of Fcγ receptor–
expressing macrophages [82]. Because 1 fused to antibody Fc (but
not to C4BP) potentially induces antibody-dependent cell cytotoxity
(ADCC), it will be interesting to investigate whether differences pre-
vail in the enhancement of intratumoral T eff/T reg cell ratio upon tu-
mor treatment with these compounds.
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1  Introduction
Enzymes play an increasingly important role in organic 
synthesis, especially in the pursuit of green chemistry 
[1–3]. To this date the use of enzymes as catalysts is lim-
ited due to their low stability, low degree of recyclability 
and the requirement of cofactors. These disadvantages 
have been overcome at least in part by enzyme immo-
bilization on solid phase [4, 5]. In order to make enzyme 
immobilization economically more attractive, methods 
are required allowing for high-density enzyme immobili-
zation without extensive and costly enzyme purification. 
We recently described a technique for the immobi-
lization of enzymes on inclusion body particles that are 
formed in Escherichia coli cells upon high-level expres-
sion of a poly-p-hydroxybutyrate (PHB) synthase (PhaC) 
from Cupriavidus necator [6]. Due to the engineered 
coiled-coil interaction of an amino-terminally fused nega-
tively charged coil (Ecoil), enzymes that are fused to a 
positively charged coil (Kcoil) bind to the surface of the 
particles with high affinity (0.5  nM) and specificity [7]. 
This co-expression and self-assembly approach leads to 
high local enzyme concentrations on the particle surface 
Research Article
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production of chiral alcohols from ketones can be carried out stereo selectively with alcohol 
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solid phase for application in ketone reduction, we used an established enzyme pair consisting 
of ADH from Rhodococcus erythropolis and formate dehydrogenase (FDH) from Candida boidinii 
for NADH cofactor regeneration and co-immobilized them on modified poly-p-hydroxybutyrate 
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(200 mg galactose oxidase per g of particles (wet weight) 
[6]) comparable to scaffoldins [8]. Hence, this system pro-
vides efficient purification and immobilization of enzymes 
on “green” particles without complicated purification and 
coupling steps (Fig. 1). 
Other frequently used immobilization techniques e.g. 
non-covalent adsorption or deposition, covalent attach-
ment, entrapment in a polymeric gel, membrane, as well 
as capsule and cross-linking of enzymes [9–12] mostly 
require purified enzymes. PhaC particles can be cost-
effectively produced in E. coli cells within a few hours 
and easily purified by cell disruption and centrifugation. 
Due to the highly specific coiled-coil interaction crude cell 
lysates can be used for particle immobilization [6].
Conceptually, such enzyme capturing particles can 
serve as scaffolds for co-immobilization of multi-enzyme 
cascades for two or more biocatalytic transformations. To 
this end, enzymes are co-immobilized on PhaC particles 
in a statistical distribution, which may allow for substrate 
channeling between the different catalysts residing in 
close proximity on the particle surface. Furthermore, the 
biodegradable particles with active immobilized enzymes 
can be removed from the reaction mixture after conver-
sion of the substrate and reused in further reactions. 
In this work, immobilization of a cofactor regenerating 
system for the production of chiral alcohols consisting of 
the two enzymes ADH and FDH on PhaC inclusion bodies 
as carrier material was performed. The alcohol dehydroge-
nase from R. erythropolis has a broad substrate spectrum 
and is able to generate chiral alcohols under the oxidation 
of NADH to NAD+ [13], while formate dehydrogenase from 
C. boidinii (FDH) regenerates the cofactor NADH (Fig. 1). 
Due to formation of carbon dioxide, the cofactor regener-
ating reaction becomes virtually irreversible [14].
The aim of the present work was to establish a model 
system for an orthogonal biocatalytic cascade reaction 
on PhaC particles for efficient substrate conversion com-
bined with cofactor-regeneration. To improve and scale-
up the reaction it was further investigated whether a 
biphasic reaction medium consisting of an organic and 
an aqueous phase could be beneficial for the process, 
since the substrate used in this study namely 4’-chloro-
acetophenone is more soluble in organic solvents than 
in water [15]. Herein we show that unpurified ADH and 
FDH expressed in E. coli cells with an aminoterminal 
coil sequence can be immobilized on PhaC inclusion 
bodies using cell lysates of respective production cul-
tures. The enzyme pair efficiently generates (S)-4-chloro-
α-methylbenzylalcohol while retaining specific activity 
upon immobilization. 
2  Materials and methods
2.1  Bacterial strains and growth conditions
Bacterial strains and plasmids used in this study are 
listed in Table  1. Escherichia coli strains were grown 
as described recently [6] in double yeast tryptone (dYT) 
medium at 37°C, supplemented with chloramphenicol 
(25  µg/mL) and/or ampicillin (100  µg/mL) to preserve 
maintenance of plasmids. Cells were grown for 3 h in pres-
ence of 1 mM IPTG (isopropyl-β-d-thiogalactopyranoside) 
for induction of inclusion body synthesis. Enzyme synthe-
sis was induced by addition of 2 µg/mL anhydrotetracy-
cline, and cells were grown at 30°C for 22 h. 
2.2  Plasmid construction
The vector pACYC-MEP contains the PhaC coding 
sequence fused to an Ecoil coding sequence as described 
in [6]. The plasmids pASK75-ADH and pASK75-FDH are 
derived from the vector pASK75 constructed by Skerra 
1994 [16] and contain the coding sequences for ADH 
and FDH, respectively. Both vectors encode for a poly-
histidine tag, an E-epitope and a Kcoil.
Figure 1. (left) Schematic illustration of the production of enzyme-covered PhaC inclusion bodies by recombinant expression in E. coli, cell disruption, joint 
incubation of the lysates and harvesting of the particles by centrifugation. (right) Schematic representation of the cofactor regenerating system consisting 
of the enzymes ADH and FDH immobilized on a PhaC inclusion bodies. ADH catalyzes the conversion of the 4’-chloroacetophenone to the chiral alcohol 
(S)-4-chloro-α-methylbenzyl alcohol, while FDH regenerates the cofactor NADH under oxidation of formate.
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2.3  Isolation of inclusion bodies
Inclusion bodies were isolated according to instruc-
tions in Steinmann et al. 2010 from 1  L of bacterial 
liquid culture after mechanical disruption of cells and 
centrifugation at 18 000 ×g for 30 min [6]. The precipi-
tated inclusion bodies were resuspended in 30 mL TBS 
(50 mM Tris, 150 mM NaCl, pH 7.8) and, after another 
centrifugation step at 10 000 ×g for 10 min suspended 
in 30 mL TBS. 
2.4   Production of cell lysates and purification  
of ADH and FDH
His-tagged Kcoil-Etag-ADH and -FDH were isolated from 
1 L of bacterial liquid culture after applying the cell sus-
pensions to a cooled cell disruptor at 1.7 kbar (TS Series; 
Constant System Ltd) and centrifugation of the lysate at 
18 000 ×g for 30 min. Enzyme-containing lysates (32 mL 
out of 1 L culture) were supplemented with 1 mM phenyl-
methanesulfonylfluoride (PMSF) and protease inhibitor 
cocktail (complete, Roche).
For standard series ADH was purified from the super-
natant via immobilized metal-ion affinity chromatogra-
phy, anion exchange chromatography and size exclusion 
chromatography. FDH was purified from the supernatant 
via immobilized metal-ion affinity chromatography and 
size exclusion chromatography.
2.5   Determination of enzyme concentrations  
within cell lysates
Anti-penta-HIS (HIS) biosensors for label-free quantita-
tion of HIS-tagged proteins designed for use in cell lysates 
were applied on the fortéBIO® Octet system. Concentra-
tion of HIS-tagged proteins was determined according to 
manufacturer’s protocol. Briefly, real-time binding data 
form serial dilutions of purified ADH and FDH were used 
to generate a calibration curve (Supporting information, 
Fig. S1). Real time binding of HIS-tagged ADH and FDH in 
a ten-fold dilution of cell lysates of ADH and FDH produc-
tion cultures was monitored and compared to the respec-
tive calibration curve.
2.6   Immobilization of enzymes onto inclusion 
bodies
Enzyme-containing lysates and inclusion bodies were 
incubated at different volume ratios and for varying time 
periods at 4°C and 1000 rpm, followed by two consecutive 
washing (100 μl TBS per mg PhaC particle) and centrifu-
gation (18 000 × g) steps.
2.7   Examination of immobilized ADH  
and FDH activity
For determination of enzyme activity 2 mg (wet weight) 
of inclusion body particles were mixed with 1.5 mL of 
the respective cell lysate. After purification as described 
above 0.017 mg of particles with immobilized ADH were 
added to a reaction buffer consisting of TBS(50  mM 
Tris-HCl, 150 mM NaCl, pH  7.8), 5 mM (S)-4-chloro-α-
methylbenzyl alcohol, 1 mM NAD+, to a final volume of 
100  μl and 0.017  mg particles with immobilized FDH 
were added to a reaction buffer containing of TBS, 5 mM 
sodium formate, 1 mM NAD+, to a final volume of 100 μl. 
NAD+ was added at last to start the reaction. Develop-
ment of NADH was followed by measurement of fluores-
cence emission at 460 nm (Infinite® M1000 PRO Tecan).
2.8   Determination of immobilized inclusion body 
loading capacity 
2 mg inclusion bodies (wet weight) were incubated with 
1.5 mL FDH cell lysate for 24 h. After two centrifugation 
and washing steps, inclusion bodies were resuspended in 
600 µL TBS. The enzyme load was determined by meas-
uring the FDH activity of 5 µL of the resuspended inclu-
sion bodies in a total volume of 100 µL TBS. The specific 
activity of soluble FDH was determined by measuring the 
velocity of NADH generation, using NAD+ and formate 
as substrates and various concentrations of FDH. The 
Table 1. Bacterial strains and plasmids used in this study
Strain or plasmid Relevant genotype or phenotype Source or reference
E. coli strains
BL21 (DE3) F–ompT gal dcm lon hsdSB(rB
-mB
-) λ(DE3 [lacI lacUV5-T7 gene 1 ind1 sam7 nin5]) [45]
BL21(DE3)(pACYC-MEP) Myc-Ecoil-PhaC (cat) [6]
BL21(DE3)(pASK75-ADH) Kcoil-Etag-His10-ADH (bla) This study
BL21(DE3)(pASK75-FDH) Kcoil-Etag-His10-FDH (bla) This study
Plasmids
pACYC-MEP P15A ori, T7 prom, Myc-Ecoil-PhaC, Cmr [6]
pASK75-ADH ColE1 ori, tetA prom, Kcoil-Etag-His10-ADH- Apr This study
pASK75-FDH ColE1 ori, tetA prom, Kcoil-Etag-His10-FDH, Apr This study
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velocity of NADH generation mediated by immobilized 
FDH was compared to the standard curve (Supporting 
information, Fig. S2).
2.9  SDS-PAGE
Protein samples were analyzed by sodium dodecyl sul-
fate-poly-acrylamide gel electrophoresis (SDS-PAGE). To 
this end, 20 µL sample volumes were mixed with 5 µL 
solubilization buffer (250 mM Tris-HCl pH 8.0; 7.5% w/v 
SDS; 25% v/v glycerol; 0.25  mg/mL bromophenol blue; 
12.5% v/v β-mercaptoethanol) and incubated at 95°C for 
5 min. Samples were loaded onto a 15% SDS-polyacryla-
mide gel. Gels were stained with Coomassie brilliant blue 
R-250 and G-250. 
2.10  Atomic force microscopy
One drop of inclusion body suspensions with and without 
immobilized FDH (in deionized water) was applied onto 
an AFM sample disc. The image was recorded in AC 
mode with an MFP3D atomic force microscope (Asylum 
Research). Images were analyzed with Gwyddion, an 
open-source software for SPM data analysis [17].
2.11   Cofactor regeneration-assisted conversion  
of 4‘-chloroacetophenone 
The reaction solution contained ADH-FDH-loaded inclu-
sion bodies (63 mg wet weight), 7.7 mM 4‘-chloroaceto-
phenone (pre-dissolved in DMSO 1:10), 100 mM sodium 
formate and 6.25 mM NAD+ in 1 mL TBS (50 mM Tris-HCl 
pH 7,5 and 150 mM NaCl). Reactions were performed at 
25°C and 1000 rpm on a shaking platform (Thermomixer 
compact; Eppendorf) for varying time periods.
Aqueous phases were overlaid with an equal volume 
of MTBE and vortexed to extract 4‘-chloroacetophenone 
and (S)-4-chloro-α-methylbenzyl alcohol for GC-MS analy-
sis. Organic phases were mixed with MTBE 1:10.
2.12   Gas chromatography-mass spectrometry  
(GC-MS) 
Gas chromatographic analyses were performed with an 
Agilent 6890N GC equipped with a 7683 autosampler and 
a 5973 mass spectrometer. Helium was used as carrier gas 
with a constant flow rate of 1 mL/min and a split ratio of 
50:1. The injector temperature was 250°C. The separation of 
4’-chloroacetophenone from 4-chloro-α-methylbenzyl alco-
hol was carried out on a DB-5-MS column (30 m × 0.25 mm, 
0.25 μm film) using a temperature program starting at 50°C 
for 2 min and then rising with a rate of 10°C/min to the final 
temperature of 300°C which was kept for 15 min. Separa-
tion of the 4-chloro-α-methylbenzyl alcohol enantiomers 
was carried out in an isothermal mode (temperature 135°C) 
using a CycloSil-B column (30 m × 0.25 mm, 0.25 μm).
Data analysis was performed using the software 
OpenChrom 0.8.0 (29.07.2013). Integration of the signals 
was carried out with the automatic integration function of 
the software (Peak Detector) or manual integration func-
tion (Manual Peak Detector) if the peak was not detected 
automatically. 
3  Results
3.1  Production of ADH, FDH and PhaC particles 
Polyhydroxybutyrate synthase (PhaC) from C. necator 
was expressed in E. coli cells as a fusion protein with 
a negatively charged α-helical Ecoil (EVSALEK)5 at the 
aminoterminus [6]. The fusion protein accumulates as 
inclusion bodies upon high-level expression at an average 
yield of 770 mg (wet weight) per liter of culture within 3 h 
post induction. ADH and FDH were produced as fusion 
proteins with an aminoterminal positively charged Kcoil 
(KVSALKE)5 with yields of 56 mg and 16 mg per liter of 
culture, respectively as determined by biolayer interfer-
ometry using the purified enzymes as reference (Support-
ing information, Fig. S1; Table S1). 
3.2   Detection of immobilized ADH-Kcoil  
and FDH-Kcoil on PhaC inclusion bodies
Enzyme immobilization on PhaC particles was investi-
gated upon incubation of cell lysates containing the solu-
ble produced enzymes with PhaC particles. The enzymes 
with a positively charged Kcoil possess a high affinity 
for the particles presenting negatively charged Ecoils on 
their surface. Both ADH and FDH specifically bound to the 
PhaC inclusion bodies via Ecoil-Kcoil interaction (Fig. 2). 
Regarding SDS-PAGE analysis of purified PhaC particles 
(Fig. 2A), nonspecific binding of other proteins occurred 
to a small extent. No efforts were made to further purify 
the inclusion bodies by extensive washing or applying 
high salt conditions. Western blot analysis revealed clear 
signals for both enzymes (Fig. 2B). FDH appeared as a 
double band, which may be indicative of partial degrada-
tion or premature end of translation.
Since immobilization can affect enzyme activity, 
activity assays were performed for both immobilized 
enzymes. To this end, ADH activity was determined by 
measurement of NADH formation in presence of (S)-4-
chloro-α-methylbenzyl alcohol as substrate for ADH and 
sodium formate as substrate of FDH [13]. ADH and FDH 
retained activities of 52 U g-1 of particles and 20 U g-1 
particles, respectively, as judged from calibration curves 
(Supporting information, Fig. S3). A unit is defined as the 
amount of enzyme that catalyzes the conversion of 1 µmol 
of substrate per minute. Low activity of FDH from C. boi-
dinii is a typical characteristic of NAD+-dependent for-
mate dehydrogenases [18].
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In order to achieve optimal conditions for enzyme 
immobilization, we examined, to what extent the num-
ber of immobilized enzyme increased over time and 
when equilibrium or a saturation of the particles was 
achieved. To this end, an excess of enzyme containing 
cell lysates of production cultures were incubated with 
PhaC particle suspension at a volume ratio of 20:1 for 
different time spans varying between 30  min to 24  h. 
Enzyme activity was determined after inclusion body 
centrifugation and washing using a fluorescence-based 
assay (Supporting information, Fig. S3). We observed an 
increase of the amount of immobilized enzyme on the 
PhaC particles with prolonged incubation time (Sup-
porting information, Fig. S4). Hence, an incubation time 
of 24 h was used for all further experiments. Comparison 
of the velocity of NADH generation by immobilized FDH 
with a standard curve of soluble FDH revealed capturing 
of 50% of FDH from lysate onto particles after 24 h (20:1 
FDH:PhaC volume ratio), assuming the same specific 
activity of the immobilized enzyme as in lysate. 190 μg 
FDH were immobilized on 1  mg particles (Supporting 
information, Fig. S2), which is consistent with the find-
ings of our previous publication for galactose oxidase 
immobilization [6].
Next, we sought to determine an optimal ratio of inclu-
sion body to FDH/ADH (PhaC:FDH:ADH) for maximum 
substrate throughput by incubating PhaC particles with 
varying amounts of both enzymes for 24 h (Supporting 
information, Fig. S5A). Titration of enzyme accumulation 
on the particle surface revealed that maximum substrate 
through put on particles was achieved by mixing PhaC 
particles with ADH and FDH containing cell lysate at a 
volume ratio of 1 : 5 : 5, PhaC (1 mg) : FDH (0.2 mg) : AD
H (0.6 mg) (Supporting information, Fig. S5). Conversion 
of 4´-chloroacetophenone to (S)-4-chloro-α-methylbenzyl 
alcohol was confirmed by GC-MS.
3.3   Analysis of enzyme-loaded PhaC inclusion 
bodies by atomic force microscopy
We further investigated the structure and size distribu-
tion of PhaC inclusion body particles by atomic force 
microscopy (AFM) (Fig. 3). A suspension of particles with 
or without immobilized enzyme was applied onto an AFM 
disc and recorded in AC mode with a MFP3D atomic force 
microscope (Asylum Research). AFM recordings showed 
that PhaC inclusion bodies appear as round particles that 
form small clusters (Fig. 3A). Pure PhaC particles had an 
Figure 2. Analysis of enzyme immo-
bilization by SDS-PAGE (A) and west-
ern blot (B). (A) Coomassie-stained 
SDS-PAGE of ADH (43,4 kDa) and 
FDH (47,7 kDa) immobilized on PhaC 
(70,2 kDa) particles. (B) Western blot 
of a homologous SDS-PAGE after 
immunostaining with penta-his and 
anti-mouse-AP antibodies for specific 
detection of ADH and FDH. M, molecu-
lar weight marker with size indicated 
in kDa. 
Figure 3. (A) AFM image of PhaC inclusion body particles. PhaC inclusion bodies form round shaped particles of an average size of 400 nm. (B) AFM pro-
file of an unconjugated PhaC particle. (C) Profile of an enzyme-loaded PhaC particle. 
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average diameter of 390  nm (Table  2). When FDH was 
attached to the surface of the particles, size increased of 
about 99 nm to an average diameter of 489 nm (Table 2). 
The FDH homodimer has a calculated width of ca. 8 nm 
and a length of ca. 15 nm (PDB ID 2FSS [19]). The hydra-
tion shell of proteins is about 1 nm thick [20]. Depend-
ing on the orientation of the enzyme on the surface of 
PhaC particles, an increase of about 20–34 nm would be 
expected. This may be indicative of enzyme stacking on 
the particle surface due to FDH oligomerization. 
3.4   Cofactor regeneration with co-immobilized 
ADH and FDH on PhaC inclusion bodies
The cofactor regenerating system consisting of co-immo-
bilized ADH and FDH on PhaC particles was applied to 
conversion of 4´-chloroacetophenone to (S)-4-chloro-α-
methylbenzyl alcohol using catalytic amounts of NAD+. 
Substrate turnover was analyzed after 24  h by GC-MS 
(Supporting information, Fig.  S6A). Reactions yielded 
99.7% conversion of 4´-chloroacetophenone to (S)-4-
chloro-α-methylbenzyl alcohol, while NAD+ was added in 
sub-stoichiometric amounts. These results clearly indi-
cate that co-immobilized ADH and FDH on PhaC particles 
retained activity for their substrates and formed a func-
tional cofactor-regenerating system. 
R. erythropolis ADH reportedly displays an enantiose-
lectivity of up to 99% (ee) for the reduction of 4´-chloroace-
tophenone [21]. To investigate whether enantioselectiv-
ity of ADH for the (S)-enantiomer was maintained upon 
inclusion body immobilization, extracted substances 
were applied on a chiral CycloSil-B column and analysed 
by GC-MS. The fusion protein consisting of ADH with 
an N-terminal Kcoil attached to inclusion body parti-
cles selectively formed the (S)-enantiomer (Supporting 
information, Fig.  S6B). Enantioselectivity of ADH was 
therefore not adversely affected by this immobilization 
technique.
3.5   Cofactor regeneration-assisted conversion of 
4´chloroacetophenone in a biphasic medium
Due to the low water solubility of the hydrophobic educt 
4’-chloroacetophenone, reactions were carried out at low 
substrate concentrations (5–10  mM). The presence of 
organic solvents can improve the solubility of the ketone 
but usually leads to impairment of enzyme activity. To 
address this, Gröger and colleagues developed a bipha-
sic reaction medium with an organic phase consisting 
of n-heptane [15]. This medium allowed the reduction 
of poorly water-soluble ketones by ADH at higher sub-
strate concentrations of about 10–200 mM. The biphasic 
reaction medium was tested with co-immobilized ADH 
and FDH on PhaC particles and 100  mM 4‘-chloroace-
tophenone to determine, whether the two systems can 
be combined for upscale purposes. Interestingly, we 
observed that PhaC particles accumulated at the phase 
boundary of water/n-heptane biphasic solvent (Support-
ing information, Fig.  S7). GC-MS analysis showed that 
only small fractions of 4‘-chloroacetophenone and (S)-4-
chloro-α-methylbenzyl alcohol were present in the aque-
ous phase, especially the proportion of the poorly water-
soluble educt was very low (Fig. 4A). By far the greater 
part of the substances was found in the organic phase as 
expected (Fig.  4A). Decrease of 4‘-chloroacetophenone 
and increase of (S)-4-chloro-α-methylbenzyl alcohol was 
analyzed in both phases at different time points (Fig. 4). 
Considering the sum of product and educt in the organic 
phase as 100%, 47% of product was converted after 24 h, 
61% after 48 h and 67% after 72 h (Fig. 4B). Full conver-
sion could not be achieved probably due to accumulation 
of PhaC particles with co-immobilized ADH and FDH at 
the phase border and not in the aqueous phase which is 
a better reaction environment for the enzymes and cofac-
tor, in particular for FDH which is known to be sensitive 
to organic solvents [22]. 
4  Discussion
4.1  PhaC inclusion bodies
In recent years, the concept of enzyme immobilization on 
water-insoluble particles produced in E. coli has been put 
forward mainly in the frame of production of polyhydroxy-
alkanoate (PHA) synthesis. E. coli, when endowed with all 
PHA synthesis genes are able to produce poly-3-hydroxy-
butyrate [23] that forms spherical polymer aggregates of 
approximately 300 nm size. It is known that active PHA 
synthase (PhaC) remains covalently attached to the amor-
phous hydrophobic PHA core and serves as the water-
PHA interface [24–26]. Proteins of interest such as green 
fluorescent protein [27], the β-galactosidase enzyme [28], 
the IgG binding ZZ domain of protein A [29], an anti-
β-galactosidase scFv (single-chain variable fragment of 
an antibody) [30], and mouse myelin oligodendrocyte 
Table 2. Average size of PhaC inclusion bodies with and without attached enzymes 
Type of particles Number of evaluated particles Average height (± standard error)a)
PhaC 135 390.17 ± 6.39 nm
enzyme-PhaC 138 489.86 ± 11.12 nm
a) Average height and the corresponding standard errors of PhaC and enzyme-loaded PhaC particles were calculated on the basis of 135 and 138 evaluated particles.
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glycoprotein (MOG) [31] were successfully immobilized 
onto PHA granules via expression as fusion protein with 
PhaC. This technology was also successfully used for 
the multivalent display of key antigens from pathogenic 
Mycobacterium tuberculosis or from hepatitis C virus 
aimed at generating potent vaccines [32–34].
In this work the ability of PhaC to form another kind 
of particles – inclusion bodies – was used to immobilize 
enzymes via the E/Kcoil fusion system. E/Kcoil used in 
this study were de novo designed by Hodges and col-
leagues and consist of two peptides with five heptad 
repeats [7]. The dissociation constant of the coiled coil 
interaction is Kd = 0.50 nM [7].
4.2   Immobilization of an orthogonal biocatalytic 
cascade onto PhaC inclusion bodies
We have previously shown that galactose oxidase  (GOase) 
can be captured to PhaC inclusion bodies (200 mg GOase 
per g of particles, wet weight). This loading density is 
comparable to other particle matrices that were used for 
enzyme immobilization such as cellulose, carbon nano-
tubes, mesoporous silicas, colloidal spherical polyelectro-
lyte brushes, or polystyrene nanoparticles [35–40]. Due 
to the fact that protein binding in most cases occurs via 
non-specific adsorption or chemical conjugation, enzyme 
purification is required prior to immobilization causing 
additional workload and costs. With PhaC particles, both 
particle generation and enzyme immobilization can be 
performed simultaneously obviating the need of enzyme 
purification, since enzyme-loaded particles can be iso-
lated from cell lysates by simple centrifugation and puri-
fied in very few washing steps. In this work, we tried 
to expand the scope of application of this strategy by 
co-immobilization onto inclusion bodies of both a cofac-
tor-requiring enzyme, i.e. alcohol dehydrogenase and 
a cofactor-regenerating enzyme, in this case a formate 
dehydrogenase. The combination of an ADH with FDH 
presented here for cofactor regeneration represents a clas-
sical example of an orthogonal biocatalytic cascade reac-
tion wherein the enzymatic conversion of the substrate 
into the product is coupled with further reactions in order 
to regenerate cofactors or cosubstrates, or to remove by-
products [41]. ADH/FDH mediated ketone reduction via 
E. coli whole cell biocatalysis has been extensively stud-
ied by Gröger and coworkers [42]. This enzyme combina-
tion was used for the conversion of the model substrate 
4’-chloroacetophenone to (S)-4-chloro-α-methylbenzyl 
alcohol. The major advantage of whole cell biocatalysts 
is that enzymes do not need to be isolated and purified 
and in some cases the cofactors do not need to be added 
to the reaction medium. The disadvantages compared to 
isolated enzymes in some cases are lower yields, longer 
reaction times and unwanted secondary products gener-
ated by other enzymes present in the cell [43]. 
Immobilization of ADH was earlier performed using 
support materials like Eupergit® via covalent bond for-
mation or Ni-NTA-beads (Qiagen) via a hexa-histidine 
tag fused to the C-terminus [43], but to the best of our 
knowledge no biotechnologically produced material was 
used for the purpose of immobilization so far. 
In our previous work, co-expression of inclusion bod-
ies and decorating enzyme was performed. Here, a modu-
lar system was anticipated that allows for the separate 
synthesis of PhaC inclusion bodies and both enzymes 
to achieve maximal expression levels (Fig. 2). The major 
advantage of this experimental setting is that no optimi-
zation of enzyme expression upon co-expression of inclu-
sion bodies is required and, more importantly, optimal 
ratios of inclusion bodies to enzymes can be determined 
simply by varying volumes of the respective cell lysate to 
be used in mixing experiments. 
By immobilization of ADH and FHD enzymes on PhaC 
particles competition with other enzymes or substrates is 
Figure 4. GC-MS analysis of a biphasic 
reaction catalyzed with enzyme-loaded 
PhaC particles. (A) GC-MS analysis of 
aqueous and organic phase distribution 
of educt 4´-chloroacetophenone and 
product (S)-4-chloro-α-methylbenzyl 
alcohol at different time points in aque-
ous and organic phase. (B) Percent 
conversion of 4´chloroacetophenone to 
(S)-4-chloro-α-methylbenzyl alcohol at 
different time points. 
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avoided. Unpurified ADH and FDH specifically bound onto 
PhaC particles and retained their activity as well as their 
enantioselectivity. A suitable ratio of ADH:FDH:PhaC 
particles was determined during this work and showed 
total conversion of 4´-chloroacetophenone to (S)-4-chloro-
α-methylbenzyl alcohol using catalytic amounts of the 
cofactor. Enantiopurity of the product was analyzed by 
chiral GC-MS, which resulted in >99% (ee) purity of the 
(S)-enantiomer, which was reported before for ADH of R. 
erythropolis [21].
4.3  Upscale in biphasic reaction medium 
Further, a biphasic reaction medium was tested for scale-
up purposes. The use of a biphasic reaction medium with 
an aqueous phase and an organic phase offers the pos-
sibility that poorly water-soluble organic substrates such 
as 4´-chloroacetophenone can be dissolved in a suitable 
organic solvent at higher concentrations [14]. Buchholz 
and coworkers identified a reaction medium consisting 
of 10–20% n-heptane to be compatible with the sensitive 
enzyme FDH (12). When using an n-heptane to aqueous 
buffer at a ratio of 1:5 and ADH/FDH loaded onto PhaC 
inclusion bodies full conversion of 4´-chloroacetophenone 
to (S)-4-chloro-α-methylbenzyl alcohol was not observed. 
This is probably caused by the fact that the enzyme 
loaded particles accumulated at the interphase of organic 
solvent and buffer (Supporting information, Fig. S7). Inter-
estingly, PhaC particles devoid of coupled enzyme dis-
played a homogenous suspension in the water phase and 
no interface formation. The reason for this may lie in the 
fact that unloaded particles have a large surface density 
of negative charge due to the presence of the charged 
Ecoil extension, which may support the solubilization 
in the aqueous phase (Fig. S7). Whether deactivation of 
the organic solvent-sensitive FDH or reduced availability 
for ADH and FDH at the interphase of the water-soluble 
cofactor NAD+ which can be expected to remain in the 
aqueous phase or a combination of both accounts for 
the observed incomplete conversion of 4´-chloroaceto-
phenone to (S)-4-chloro-α-methylbenzyl alcohol (Fig.  4) 
requires further investigation. 
4.4  Concluding remarks
In conclusion, the described method provides the oppor-
tunity to immobilize multiple enzymes that are required 
for cascade reactions [3] or for cofactor regeneration on a 
capturing material that is conveniently and inexpensively 
produced by E. coli. A high surface load of enzyme can be 
achieved by non-covalent immobilization through coiled-
coil formation and the resultant enzyme-loaded particles 
can be conveniently purified by repeated washing and 
centrifugation steps [6]. Since the capturing material 
and the enzymes can be produced separately, optimal 
enzyme ratios of surface-captured biocatalysts can be 
adjusted simply by varying cell lysate volumes. The 
method requires enzyme modification via introduction 
of a (KVSALKE)5 residue sequence that can be attached 
genetically either at the carboxy- or the amino-terminus, 
giving also the opportunity to control the orientation of 
the enzyme on the surface. A minor drawback of our 
strategy may lie in the fact that the relative amount of 
the immobilized enzymes can easily be controlled but 
not their spatial arrangement. A promising alternative 
approach has been described recently that relies on 
enzyme self-assembly on a designed scaffolding protein 
through the high-affinity interaction between a dockerin 
domain in each enzyme and multiple cohesins in the 
synthetic scaffoldin, thus allowing for an oriented spatial 
arrangement of the enzymes. In this setting, a genetically 
fused cellulose-binding domain allows for the immobiliza-
tion on solid regenerated amorphous cellulose [39, 44]. It 
will be interesting to investigate, whether the scaffoldin 
and our bioparticle technology can be combined aimed 
at immobilizing enzyme cascades in an oriented manner 
on the surface of inclusion body particles via coiled coil 
interaction by replacing the cellulose-binding domain 
with a Kcoil sequence. 
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Supporting*Information*
*
1. Experimental details 
1.1 Cell lines  
Human colon cancer cell line COLO 205 and human embryonic kidney cell line HEK-293 
were grown in Dulbecco´s Modified Eagle´s Medium (Sigma-Aldrich) completed with 10 % 
fetal bovine serum at 37 °C. 
1.2 Reagents 
Soluble TRAIL and soluble DR5 (TRAIL-R2) were obtained from Peprotech. Cell viability 
assay CellTiter 96 Aqueous One Solution Cell Proliferation Assay (MTS) was purchased 
from Promega. For FACS analysis of apoptotic cells ROTITEST-ANNEXIN V was obtained 
from Carl Roth. 
1.3 Cloning of expression vectors for C4BP and DR5TP fusion proteins 
The coding sequence of the scaffold C4BP with an N-terminal oligo-glycine tag protected by 
a TEV-cleavage site and a C-terminal SortaseA tag was PCR amplified with the primers 
GGG-C4BP_BglII_up (5´gcgcgcagatctggaaaacctgtacttccagggcggcgcgcacatggggtgg-3´) and 
LAETGGS_XhoI_lo (5´gcgcgcctcgagttagctgccaccggtttccgccaggattagttctttatccaaag-3´) or 
LPESGGS_XhoI_lo (5´gcgcgcctcgagttagctgccaccgctttccggcaggattagttctttatccaaag-3´), 
digested with the restriction enzymes BglII and XhoI and ligated in frame with the thioredoxin 
and C4BP coding sequence with pET32a-Trx-C4BP linearized with the same restriction 
enzymes.   
For the expression of DR5TP C4BP fusion proteins, the DR5TP coding sequence was PCR 
amplified with oligonucleotides DR5TP_up_BamHI (5´-gcgcgcggatccggagaacctgtattttcagggtg 
gtggttgggattgtctggataatcgtattggtc-3´) and DR5TP_lo_NcoI (5´-gcgcgccctggaaccaccacccagttt 
aacacactgacgacgaccaatacgattatccagac-3´), digested with the restriction enzymes BamHI and 
NcoI and ligated in frame with the thioredoxin and C4BP coding sequence with pET32a-Trx-
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C4BP linearized with the BglII and NcoI restriction enzymes for N-terminal fusion. For C-
terminal fusion oligonucleotides C4BP_BglII_up and DR5TP_lo_EcoRI (5´-
gcgcgcgaattcttacagtttaacacactgacgacgaccaatacgattatccagacaatcccaacc accggtttccggcag-3´) 
were used for PCR amplification. PCR products were digested with BglII and EcoRI and 
ligated with pET32a-Trx-C4BP linearized with the same restriction enzymes.  
1.4 Recombinant production of Fc scaffold (4), C4BP scaffolds (5 and 6) and SortaseA 
variants 
An Fc construct was expressed using transiently transfected HEK293-6E suspension cells 
cultured in FreeStyle™ F17 Expression Medium (Life Technologies) supplemented with 4 
mM L-glutamine (Sigma) and 50 µg/ml G418 at 100 rpm shaking speed, 37 °C and 5 % CO2. 
2 × 106 viable cells per ml were seeded the day before transfection in medium without 
antibiotics. Cells were transfected using 3 µg 25 kDa linear polyethylene imine (Polysciences) 
according to manufacturer’s protocol. Medium was supplemented with 0.5 % tryptone the 
next day. Fc was purified from the supernating medium after 5 days of incubation using an 
ÄKTA FPLC purifier system (GE Healthcare) equipped with a protein A HP column (1 mL 
HiTrap Protein A HP column; GE Healthcare, Uppsala, Sweden) following dialysis against 
PBS. 
Sortase A and C4BP production and purification was performed as described.[1] Briefly, BL21 
(DE3) cells were transformed with the corresponding expression vector (pET32a-Trx-C4BP 
for thioredoxin C4BP fusion protein production, pET29b for SrtA1-3 production) and grown 
in 1 l dYT medium supplemented with 100 mg/l ampicillin (pET32a-Trx-C4BP) or 50 mg/l 
kanamycin (pET29b-SrtA) at 37 °C and 180 rpm to an optical density at 600 nm (OD600) of 1. 
Expression of the proteins was induced with 1 mM IPTG (isopropyl β-D-1-thiogalacto-
pyranoside). Cells were incubated at 30 °C (in case of thioredoxin C4BP fusion proteins) or 
37 °C (in case of Sortase A) and 180 rpm for 3 h following centrifugation at 6800 g for 15 
min at 4 °C.  
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Cells were disrupted with a cooled cell disruptor at 1.7 kbar (TS Series, Constant System Ltd) 
and lysates were centrifuged at 18000 g at 4 °C for 30 min. The His-tagged proteins were 
purified from the cleared lysate using an ÄKTA FPLC purifier system (GE Healthcare) 
equipped with a His-Trap HP column (1 mL HisTrap HP column; GE Healthcare, Uppsala, 
Sweden) followed by dialysis against TBS (50 mM Tris-HCl pH 7.5, 150 mM NaCl). 
1.5 Chemical synthesis of peptides 1, 2, 3, 7-8 
The sequences of DR5TP bearing either an N-terminal GGG (1 and 2) or C-terminal 
LAETGGS (3) sortase A tags were assembled by Fmoc solid-phase peptide synthesis (Fmoc-
SPPS) using a fully automated microwave-assisted CEM Liberty blue® platform on 0,1 mmol 
scale.  
D-(+)-Biotin was N-terminally coupled on solid support upon pre-activation with 2-(1H-
benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) and 
diisopropylethylamine (DIEA) in DMF within 1h at ambient temperature (peptide 1).  
After cleavage from polymeric support, oxidative folding towards formation of a disulfide 
bridge was performed in 100 mM ammonium carbonate buffer (pH 8.9, concentration of a 
peptide 1 mg/ml). Folding of the resulting peptides 1 (biotinylated), 2 and 3 was monitored by 
analytical RP-HPLC and LC-ESI-MS. The folded peptides were purified after 12-24 h of air 
oxidation and lyophilized. 
Peptides 7 and 8 were synthesized by automated Fmoc-SPPS (microwave-assisted Liberty 
Blue platform) on a RAM resin (Agilent), without end-deprotection of the N-terminus. The 
orthogonal Mtt protecting group of lysine’s side chain was cleaved by incubation with DCM-
TES-TFA (97:2:1; 5 × 5 ml) for 10 minutes, following by washing with DCM (3 × 5 ml), and 
DMF (3 × 5 ml).  
For peptide 7, the GGG elongation was made through the side chain of lysine using the 
H-GGG-OH building block and standard HBTU/DIEA activation, followed by the N-terminal 
deprotection and acidolytic cleavage from the support.  
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For peptide 8 the azide-bearing moiety was manually attached to the ε-amine group of Lys 
upon double coupling of 4 equiv. 4-azidobutyric acid in the presence of 3.9 equiv. of HBTU 
and 8 equiv. of DIEA for 30 minutes at ambient temperature. Finally, the N-terminal Fmoc 
protection was cleaved with 20% piperidine in DMF at room temperature for 5 min. 
Afterwards, the peptide was washed with DMF (3×), DCM (3×) and DEE (3×) and cleaved 
from the solid support using the standard cleavage cocktail with DTT added in the mixture in 
order to prevent unwanted oxidation.  
The macrocyclization via the formation of a disulfide bond was conducted in 100 mM 
(NH4)2CO3 aq. (1 mg mL−1, pH = 8.4) over night monitored by analytical RP-HPLC. The 
dried peptide was obtained after freeze-drying.  
For the successive copper-click reaction, the LPESGGS counterpart was assembled by 
automated Fmoc-SPPS followed by coupling of propiolic acid N-terminally using the same 
protocol as for the coupling of azidobutyric acid. After drying of peptide-resin in vacuo, 
cleavage of the peptide from the solid support was conducted using a standard cleavage 
cocktail TFA-H20-anisole-triethylsilane (47:1:1:1, V:V:V:V). After 2 h of shaking the peptide 
was precipitated and washed 3 × 40 mL with diethyl ether.  
The copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) was conducted with 1 equiv. of 
the azide-bearing peptide, 4 equiv. of the alkyne bearing one, 4 equiv. CuSO4·5H2O, 4 equiv. 
sodium ascorbate, and 8 equiv. DIEA with gentle shaking overnight at ambient temperature.  
Peptides 7 was isolated using preparative HPLC and analyzed by LC-MS, and peptide 8 was 
used without further purification after lyophilization. 
1.6 SortaseA-mediated ligation  
For the ligation of DR5TP derivatives 2 and 3 to the N- or C-terminus of heptameric, folded 
C4BP, sortase A variants 4S9, 2A9 and Mut5 were used.[2] The reaction was performed in 
TBS (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10 mM CaCl2) using at least a 10-fold excess 
of the peptide per coupling site within the scaffold and 0.2 equivalents of sortase A.  
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Fusion proteins 16, 17 and reaction mixtures of SrtA-catalyzed ligations towards compounds 
9-15, were analyzed by SDS-PAGE under reducing as well as non-reducing conditions and 
purified by size exclusion chromatography using a Superdex 200 10/300 column on an ÄKTA 
purifier FPLC/system (GE Healthcare). TBS at neutral pH was used as eluent at a flow of 
0.75 ml/min.   
1.7 ELISA binding studies  
Compounds 1, 4-6, 9-13, 16 and 17 were examined in ELISA binding assays with 
extracellular domain of DR5. DR5 (Peprotech TRAIL-R2; 50 ng/well) was immobilized onto 
MaxiSorp® 96 well plates (Nunc)overnight in 100 mM sodium carbonate buffer (pH 9.4) at 
4 °C. Plates were blocked with 3 % bovine serum albumin (BSA) in PBS (pH 7.4) within 1 h 
at ambient temperature. Serial dilutions of samples in PBS (140 mM NaCl, 10 mM KCl, 6.4 
mM Na2HPO4, 2 mM KH2PO4, pH 7.4) with 1 % BSA were incubated on plates for 1 h at 
room temperature. After 10 washing steps with PBST (PBS + 0.05 % Tween50), in case of 
His-tagged protein, a mouse monoclonal anti-oligohistidine antibody (Qiagen) was added and 
incubated for 1 h in 50 µl PBS (1:5000 dilution) with 1 % BSA at ambient temperature. After 
repeated washing, a secondary anti-mouse antibody horseradish peroxidase (HRP)-conjugate 
(Sigma-Aldrich) was incubated with the plates for 1 h in 50 µl PBS (1:5000 dilution) at 
ambient temperature. In case of biotinylated peptide 1 an extravidin-HRP conjugate was used 
for detection. After final washing of the plates with PBST, bound samples were detected with 
3,3',5,5'-tetramethylbenzidine (TMB, Sigma Aldrich) as a chromogenic substrate for HRP. 
The reaction was terminated after 30 min of incubation at ambient temperature by the addition 
of 0.2 M HCl and absorbance was measured subsequently at 450 nm in a Tecan ELISA 
reader.  
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1.8 Cell viability assay  
COLO205 and HEK293 cells were seeded in 96-well plates at a density of 1104 viable cells 
per well and 0.5104 viable cells per well, respectively, in a total volume of 80 µl DMEM 
supplemented with 10 % calf serum. On the next day serial dilutions of sample in 20 µl (PBS) 
were added to the cells. After incubation for 48 h at 37 °C and 5 % CO2 cell titer 96 aqueous 
one solution reagent (Promega) was added to the cells according to manufacturers protocol 
and absorbance was measured at 485 nm in a Tecan ELISA plate reader. Background 
absorbance from wells without cells was subtracted from all absorbance values to yield the 
correct absorbance. Absorbance of cells treated with PBS was set as 100 % viability and cell 
viability was plotted versus the concentration of a sample.  
1.9 FACS analysis  
An Annexin-V staining kit (ROTITEST) was used for the staining and discrimination of 
apoptotic and necrotic cells. For that purpose COLO205 and HEK293 cells were seeded in a 
24 well plate at a density of 3 105 viable cells per well in 400 µl DMEM supplemented with 
10 % calf serum. After 12 h of incubation at 37 °C and 5 % CO2 cells were treated with 
100 µl of sample/stimulant at a defined concentration in PBS. After 2-3 h of incubation, the 
supernatant was collected and the remaining adherent cells were detached by trypsination and 
added to the collected supernatant. Cells were treated following manufacturer’s protocol and, 
finally, analyzed by FACS (BD Influx). 
1.10 Reversed-phase HPLC  
A Phenomenex Hypersil 5u BDS C18 LC column (150 x 4.6 mm, 5 µm, 130 Å) was used on 
an analytical RP-HPLC system from Varian, model 920-LC, for the analysis of peptides. 
Peptides were isolated using a semi-preparative RP-HPLC (Varian) equipped with a 
Phenomenex Luna 5u C18 LC column (250 x 12.2 mm, 5 µm, 100 Å). We used water as 
eluent A and 90 % aq. acetonitrile as eluent B, both supplemented with 0.1 % trifluoroacetic 
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acid (TFA).  
1.11 LC-ESI-MS analysis  
Mass spectra were recorded with a Shimadzu LCMS-2020 equipped with a Phenomenex 
Jupiter 5u C4 LC column (50 × 1 mm, 5 µm, 300 Å). 0.1 % aq. formic acid (LC-MS grade) 
was used as eluent A and acetonitrile containing 0.1 % aq. formic acid (LC-MS grade) as 
eluent B.  
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2. Assembly of multivalent constructs 
!
Figure S1: DR5TP multivalent constructs reported in the literature.[3]  !
Table S1. Precursor scaffold molecules 
Scaffold Cleavable 
tag 
N-terminal 
conjugation site  
Architecture C-terminal  
conjugation site 
4 ENLYFQ GGG Fc LPESGG 
5 Trx-ENLYFQ GGG C4BP LPETGGGGG 
6 Trx-ENLYFQ GGG C4BP LPESGGS !!
!
 
Figure S2: Sortase A catalysis. SortaseA cleaves an amino acid located C-terminally to threonine (or serine in 
case of sortase A 4S9) and catalyzes the ligation of an oligoglycine labeled probe. 
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Figure S3: Sortase A-mediated conjugation of peptides 2 and 3 with Fc-scaffold 4. A) Generation of conjugate 9 
by ligation of peptide 2 to C-termini of Fc (4) under sortase 4S9 catalysis. B) TEV cleavage of tag1 liberates 
tag2 making it accessible for the sortase 2A9-mediated ligation with peptide 3. C) Sortase 2A9 mediated ligation 
of peptide 3 onto N-termini of TEV-cleaved scaffold 4 results in conjugate 10.  !!
Table S2: SortaseA variants used in this work. 
Abbreviation Used Sortases Reference Recognition 
sequence 
SrtA1 SrtA Mutant 5 Chen et al. [2a] LPETG 
SrtA2 SrtA 4S9 Dorr et al.[2b] LPESG 
SrtA3 SrtA 2A9 Dorr et al.[2b] LAETG !
!
Figure S4: Production of tagged C4BP (tag1 = thioredoxin (Trx) with TEV-cleavage site-GGG; tag4 = 
LPESGGS). The cell produces single thioredoxin-C4BP alpha-chain molecules, which self-assemble into a 
hepatmeric scaffold. Upon air oxidation the monomers are covalently linked by disulfide bonds towards a 
particular architecture.[1a] 
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Table S3. Synthetic constructs used in this study. 
Construct Molecule Assembly Function 
1 Biotin-GGG-WDCLDNRIGRRQCVKL SPPS binder 
2 GGG-WDCLDNRIGRRQCVKL SPPS binder 
3 WDCLDNRIGRRQCV-LAETGGS SPPS binder 
4 TEV-GGG-Fc-LPESGG recombinant scaffold  
5 Trx-TEV-GGG-C4BP-LPETGGGGG recombinant scaffold  
6 Trx-TEV-GGG-C4BP-LPESGGS recombinant scaffold 
7 WDCLDNRIGRRQCV-K(-GGG)L SPPS binder 
8 WDCLDNRIGRRQCV-K(-LPESGGS)L SPPS binder 
9 TEV-GGG-Fc-2 (2+4) SrtA mediated conjugate 
10 3-Fc-LPESGG SrtA mediated conjugate 
11 3-Fc-2 SrtA mediated conjugate 
12 Trx-TEV-GGG-C4BP-2 SrtA mediated conjugate 
13 Trx-TEV-GGG-C4BP-7 SrtA mediated conjugate 
14 3-C4BP-LPESGGS SrtA mediated conjugate 
15 8-C4BP-LPESGGS SrtA mediated conjugate 
16 Trx-C4BP-2  recombinant conjugate 
17 Trx-DR5TP-C4BP-LAETGGS  recombinant conjugate 
18 Anti-Fc IgG peroxidase conjugate*   *commercially available!!
Table S4: Multivalent constructs targeting DR5. 
Scaffold/ligand Valence Chemistry KD EC50 Source 
DR5 targeting peptide* 1  129 nM  [3a] 
Bis-succinimidyl 
carboxymethoxy 
acetate/synthetic peptide  
2 Amide** 1.24 nM  [3a] 
Adamantane tris-
succinimidyl ester/synthetic 
peptide 
3 Amide** 0.88 nM  [3a] 
Adamantane tricarboxylic 
acid derivative/synthetic 
peptide 
 
3 Amide** 91 pM 31.23 nM [3b] 
Second generation 
dendritic adamantane 
azide derivative/synthetic 
peptide 
6 CuAAC 7.1 pM 255.64 nM [3b] 
Metal ion/TRAIL*** 3 Zn complex with 
cysteine thiols 
270 pM 50-100 pM [4] 
Nanobody Pentamer 5 Amide 
(recombinant) 
< 1012 M < 0.001 nM [5] 
C4BP/synthetic peptide 7 Amide (SrtA-
catalyzed) 
25 nM 12 nM This 
work 
C4BP/fused peptide 7 Amide 
(recombinant) 
23 nM 3 nM This 
work *solitaire peptide; **via side chain of lysine; ***Zn complex comprising three sTRAIL monomers!
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3. Additional activity assays 
!
Figure S5: ELISA affinity titration of DR5 binding Fc-conjugates 9, 10 and 11. DR5 was coated to 96 well 
plates (50 ng/per well) and dilutions of bivalent (9 and 10) and tetravalent (11) Fc-conjugates were titrated to the 
plates. Measurements were performed in triplicate. !!!
!
Figure S6: AnnexinV (apoptotic cells) and propidium iodide (necrotic cells) staining of COLO205 cells treated 
with PBS as negative control (A) or soluble TRAIL (sTRAIL) for 2 h (B) and 3 h (C). !
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Figure S7: AnnexinV (apoptotic cells) and propidium iodide (necrotic cells) staining of HEK293 cells treated 
with PBS as negative control (A), compound 5 (B), peptide 2 (C), compound 16 (D) or soluble TRAIL (E). !
 
4. Induction of apoptosis by heptavalent C4BP-nanobody fusion !
!
Figure S8: Left: ELISA affinity titration of DR5 binding Nanobody-C4BP fusion protein (KD = 16 nM). Right: 
Cytotoxicity assay with Nanobody-C4BP fusion protein on COLO205 cells (EC50 = 4 nM). !
To further examine the application range of our templated, modular approach, we attached a 
DR5 binding nanobody[6] on C4BP scaffold and conducted ELISA binding studies and 
cytotoxicity assays. Being oligomerized to a linear tetramer, this high-affinity nanobody is 
known to induce apoptosis with high efficiency. In our recombinantly produced heptavalent 
construct the binding nanobody units (about 15 kDa) were located N-terminally since this 
position is preferred for the bulky fusion partners. In our hands, this construct demonstrated 
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rather good binding to DR5 as well as pronounced cytotoxicity in cancer cells, which is, 
however, significantly impaired compared to the reported linear tetramers.[5] This difference 
could be obviously caused by the suboptimal architecture of the nanobody-comprising heptad. 
Nevertheless, these results show that our approach can be applied to the generation of more 
sophisticated oligovalent architectures possessing binding moieties other than oligopeptides. !!
5. HPLC, LC-ESI-MS, and SDS PAGE data !!
!
Figure S9. Exemplary HPLC monitoring of oxidative folding towards 2 at 220 nm. Top: reduced precursor. 
Bottom: reaction mixture containing oxidized 2.  
 
 
!
Figure S10. ESI-MS spectrum of 2. Positive ionization mode. Calc. MW: 2143.47, meas. m/z: 1072.7 
[M+2H]2+, 715.5 [M+3H]3+, 536,9 [M+4H]4+, 429.7 [M+5H]5+. !!
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Figure S11. ESI-MS spectrum of 3. Positive ionization mode. Calc. MW: 2346.62, meas. m/z: 1174.5 
[M+2H]2+, 783.3 [M+3H]3+, 587.7 [M+4H]4+. 
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Figure S12. ESI-MS spectrum of 1. Calc. MW: 2369.78, meas. m/z: 1187 [M+2H]2+, 791 [M+3H]3+, 594 
[M+4H]4+. !!
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Figure S13. ESI-MS spectrum of 7. Positive ionization mode. Calc. MW: 2143.47, meas. 1072.7 [M+2H]2+, 
715.5 [M+3H]3+, 536.9 [M+4H]4+. !!
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Figure S14. ESI-MS spectrum of 8. Positive ionization mode. Calc. MW: 2780.5, meas. m/z: 1391.1 [M+2H]2+, 
927.6 [M+3H]3+, 695.6 [M+4H]4+. !!
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Figure S15: Sortase-mediated assembly of conjugates 9 (29.7 kDa) and 11 (31.3), (TEV-cleavage of 9 (26.8 
kDa) and precursor molecule 4 (27.6 kDa). Ligation of 2 to 4 for the generation of 9 mediated by sortase (4S9) 
and 3 to 9 for the generation of 11 by sortase (2A9) monitored by SDS-PAGE. –βMe: no β-mercaptoethanol 
added (non-reducing conditions). M: blue protein standard. 
 
!
Figure S16: Left panel: Sortase A-mediated assembly of conjugate 10 (29.1 kDa) and TEV cleaved precursor 
molecule 4 (27.6 kDa). Right panel: Ligation of 2 to 10 for the generation of 11 mediated by sortase (4S9) 
monitored by SDS-PAGE. M: blue protein standard. !
! !
Figure S17: Sortase A-mediated assembly of conjugates 12 (27.2 kDa), 13 (27.2 kDa) and precursor molecule 5 
(25.6 kDa) (left panel). TEV-cleaved 6 (8.5 kDa) and 16 (10.6 kDa) as well as conjugate 14 (10.9 kDa) (right 
panel). 5, 12 and 13 harbor an N-terminal thioredoxin, which is cleaved off in case of 14 and 16.  
Ligation of peptide 2 to scaffold 5 generates conjugate 12 and of peptide 7 to scaffold 5 generates conjugate 13.  
Conjugation of peptide 3 onto TEV-cleaved scaffold 6 by SrtA3 (2A9) generates 14 (monitored by SDS-PAGE).  
–βMe: no β-mercaptoethanol added (non-reducing conditions). M: blue protein standard. !
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Figure S18: SDS-PAGE of recombinant production of 16 (27.2 kDa), 17 (27.6 kDa) and precursor molecule 5 
(25.6 kDa) as thioredoxin fusion. –βMe: no β-mercaptoethanol added (non-reducing conditions). M: blue protein 
standard. !!!
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5.2. Supplemental information of the publication: Cystine-knot peptides targeting cancer-
relevant human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) 
 
Cystine-knot peptides targeting cancer-relevant human cytotoxic T 
lymphocyte-associated antigen 4 (CTLA-4) 
 
Franziska Maaß, Joycelyn Wüstehube-Lausch, Stephan Dickgießer, Bernhard Valldorf, Michael 
Reinwarth, Hans-Ulrich Schmoldt, Matin Daneschdar, Olga Avrutina, Ugur Sahin, and Harald Kolmar 
 
 
Supplementary Information 
 
Figure S1. HPLC and ESI-MS analysis of synthetic peptide 2 
Binding of biotinylated synthetic peptide 2 to CTLA-4-overexpressing cells 
Figure S2. Immunofluorescence staining of CTLA-4-overexpressing cells. 
Figure S3. Schematic representation of the Fc-fused reference protease inhibitor and its inhibitory 
activity against its target protease matriptase 
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Figure S1. HPLC and ESI-MS analysis of synthetic peptide 2. 
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Binding of biotinylated synthetic peptide 2 to CTLA-4-overexpressing cells 
 
To investigate binding of 1 to CTLA-4-overexpressing CHO-K1-cells (CHO-K1-CTLA-4), an 
immunofluorescence staining was conducted. CHO-K1-MOCK cells and a control miniprotein, which 
does not bind to CTLA-4, were used as controls to exclude unspecific binding of the miniprotein to 
different surface proteins. In comparison to the control cells (CHO-K1-MOCK, Figure S2, C), a 
specific binding of the biotinylated derivative of 1, namely, synthetic peptide 2 that was preassembled 
on Cy3-conjugated streptavidin was detected on CTLA-4-overexpressing cells (Figure S2, A). As 
expected, the control miniprotein did not bind to CHO-K1-CTLA-4 cells (Figure S2, B). 
 
 
Figure S2. Immunofluorescence staining of CTLA-4-overexpressing cells. (A) Binding of 
streptavidin-Cy3-conjugated peptide 2 to CTLA-4-overexpressing CHO-K1 cells (B) An unrelated 
miniprotein was used as control for binding on CTLA4-overexpressing cells. (C) To exclude 
unspecific binding, MC-CT-010 binding was tested on control cells (CHO-K1-MOCK). 
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Figure S3. Schematic representation of the Fc-fused reference protease inhibitor (left) and its 
inhibitory activity (right) against its target protease matriptase. The monomeric synthetic open-chain 
miniprotein MCoTIv4 inhibits matriptase-1 with a Ki of 0.8 ± 0.1 nM. MCoTIv4 was N-terminally 
fused to Fc fragments using genetic engineering. The inhibitory activities of the expressed MCoTIv4-
Fc fusion protein were determined to a Ki of 7.0 ± 0.6 nM. The slightly elevated Ki is most likely due 
to steric hindrance of target enzyme binding by linkage to Fc.[1] This indicates that the recombinant 
expression of this specific miniprotein yields a functional protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
K
i
	  =	  7.0	  ±	  
0.6	  nM 
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5.3. Supplemental information of the publication: Coupled Reactions On Bioparticles: 
Stereoselective Reduction With Cofactor Regeneration On PhaC Inclusion Bodies 
!
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Coupled reactions on bioparticles:  
Stereoselective reduction with cofactor regeneration  
on PhaC inclusion bodies
Valerie Spieler, Bernhard Valldorf, Franziska Maaß, Alexander Kleinschek,  
Stefan H. Hüttenhain, Harald Kolmar
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Supporting Information 
 
Coupled reactions on bioparticles: Stereoselective reduction with cofactor 
regeneration on PhaC inclusion bodies 
Valerie Spieler, Bernhard Valldorf, Franziska Maaß, Alexander Kleinscheck, Stefan H. 
Hüttenhain, and Harald Kolmar 
Supplemental Table 1: Concentration of enzymes within cell lysates or suspensions.  
Enzyme Concentration in lysate 
ADH 1.7 mg/ml 
FDH 0.5 mg/ml 
PhaC  27 mg/ml (wet weight) 
 
Cells from 1 l bacterial culture were pelleted and resuspended in 32 ml TBS (50 mM Tris, 
150 mM NaCl, pH 7.5). After disruption of the cells (cell lysate volume 32 ml), 
concentrations of ADH and FDH, respectively were determined by biolayer interferometry 
(forteBio). Ni-NTA biosensors coated with nickel-charged tris-NTA were used for 
quantitation of HIS-tagged proteins. A standard curve for each enzyme was generated using 
purified enzymes.  
 
 
 Supplemental information  88 
 
!
!"!2!"!!
Supplemental Figure 1: Concentration determination within cell lysates. Standard curves of 
purified ADH and FDH were generated (See Material and Methods). The binding rate of a 
ten-fold dilution of cell lysates from cells expressing ADH or FDH was compared to the 
standard curves. The calculated concentration of FDH is 555.9 µg/ml and of ADH is 
1647.5 µg/ml.  
 
Supplemental Figure 2: Determination of binding capacity of PhaC inclusion bodies. The 
velocity of NADH generation by soluble FDH was measured using NAD+ and formate as 
substrates and various concentrations of FDH (See Material and Methods). The velocity of 
NADH generation mediated by immobilized FDH was compared to a standard curve. 
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Supplemental Figure 3: Fluorescence based activity assay; S3A: NADH standard curve; 
S3B: NADH formation by immobilized enzyme-loaded particles (0.0167 mg wet weight). 
Formate was used as substrate for FDH and (S)-4-chloro-α-methylbenzyl alcohol for ADH. 
For experimental details see Materials and Methods section. S3C: Conversion of NAD+ to 
NADH per minute per mg of particles (wet weight). The amount of immobilized ADH-loaded 
particles (0.0167 mg wet weight) used in the assay converted 0.87 nmol of NAD+ to NADH 
per minute, while immobilized FDH reduced 0.33 nmol of NAD+ to NADH per minute (Fig. 
1B). 
 
 Supplemental information  90 
 
!
!"!4!"!!
 
Supplemental Figure 4: Influence of incubation time on enzyme activity. PhaC particles 
were incubated with FDH-containing cell lysate and enzyme activity was analyzed after 
different incubation durations. 
 
Supplemental Figure 5: Enzyme binding capacity of the PhaC inclusion bodies. 5 A: 
Columns show percentage of the product (S)-4-chloro-methylbenzyl alcohol formation after 
each time point. Particles were preincubated with lysates at a volume ratio of 10:10:1 (0.6 mg: 
0.2 mg: 1 mg) or 5:5:1 (0.3 mg: 0.1 mg: 1 mg) ADH:FDH:PhaC for 24 h (concentrations of 
enzymes within lysates see table S1). The enzyme-loaded particles were separated from the 
lysates and applied to the reaction mixture for formate-dependent ketone reduction. An equal 
volume of the lysate was equivalently treated and both were analyzed by GC-MS at each time 
point indicated. 5 B: GC-MS analysis of reactions catalyzed with PhaC particles preloaded 
with varying ADH to FDH volume ratios (10:10:1 (0.6 mg: 0.2 mg: 1 mg); 17:3:1 (1 mg: 0.07 
mg: 1 mg); 18:2:1 (1.1 mg: 0.04 mg: 1 mg); (ADH:FDH:PhaC)) to reach optimal product 
yield and cofactor regeneration. Columns show the percentage of the product (S)-4-chloro-α-
methylbenzyl alcohol after each time point.  
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Supplemental Figure 6: (A) GC-MS chromatograms of reference substances (transparent 
peaks) superimposed with reaction product (darker grey) of cofactor regeneration-assisted 
conversion of 4´-chloroacetophenone to (S)-4-chloro-α-methylbenzyl alcohol. 4´-
chloroacetophenone elutes from the column at 10.95 min while (S)-4-chloro-α-methylbenzyl 
alcohol elutes at 11.25 min. 6 B: GC-MS chromatograms of the racemate of (R)- and (S)-4-
chloro-α-methylbenzyl alcohol. (R)-4-chloro-α-methylbenzyl alcohol elutes after 13.65 min 
(S)-4-chloro-α-methylbenzyl alcohol elutes after 14.3 min and the reaction product elutes 
after 14.3 min (indicated in darker grey).  
 
 
Supplemental Figure 7: Biphasic reaction mixture. Enzyme loaded PhaC particles remain in 
the interphase (left tube). Particles without enzymes remain in the aqueous phase (right tube).  
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Abbreviations 
 
ADC Antibody-drug conjugate 
ADCC  Antibody-dependent cellular cytotoxicity  
ADH Alcohol dehydrogenase 
AFM Atomic force microscopy 
BSA Bovine serum albumin 
CDC  Complement-dependent cytotoxicity 
CDR Complementarity determining region 
CH2, CH3 Constant domain 2,3 of the heavy chain 
c-Met Hepatocyte growth factor receptor 
C-terminus Carboxy-terminus 
CTLA-4 Cytotoxic T lymphocyte-associated protein 4 
DAPI 4´,6-Diamidino-2-phenylindole 
DR4 Death receptor 4 
DR5 Death receptor 5 
DcR1 Decoy receptor 1 (TRAIL R3) 
DcR2 Decoy receptor 2 (TRAIL R4) 
ECD Extracellular domain 
EC50 Half maximal effective concentration 
EGFR Epidermal growth factor receptor 
EHD2 CH2 domain of IgE 
ELISA Enzyme-linked immunosorbent assay 
eSrtA Enhanced sortase A 
FACS Fluorescence-activated cell sorting 
FBS Fetal bovine serum 
Fc  Fragment crystallizable 
FcRn Neonatal Fc receptor 
Fcγ Fc-part of IgG1 
FcγRs IgG Fc specific receptors 
FDA US Food and Drug Administration 
FDH Formate dehydrogenase 
FITC Fluorescein isothiocyanate 
GC-MS Gas chromatography-mass spectrometry 
HER2 Human epidermal growth factor receptor 2 
HGF Hepatocyte growth factor 
IgG Immunoglobulin G 
IMAC Immobilized metal ion affinity chromatography 
KD Equilibrium dissociation constant 
Ki Inhibition constant 
LC-MS Liquid chromatography-mass spectrometry 
mAb Monoclonal antibody 
MCoTI Trypsin inhibitor from Momordica cochinchinensis 
MHD2 CH2 domain of IgM 
MWCO Molecular weight cut off 
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NADH Nicotinamide adenine dinucleotide 
N-terminus Amino-terminus 
Ni-NTA Nickel – nitrilotriacetic acid 
OPG Osteoprotegerin 
PAGE Polyacrylamide gel electrophoresis 
PCR Polymerase chain reaction 
PEG  polyethylene glycol 
PHA Polyhydroxyalkanoate 
PhaA β-ketothiolase 
PhaB acetoacetyl-CoA reductase 
PhaC Polyhydroxyalkanoate synthase 
PI Propidium iodide  
SDS Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEC Size exclusion chromatography 
SPPS Solid phase peptide synthesis 
TEV Tabacco etch virus 
TNF Tumor necrosis factor cytotoxic T lymphocyte-associated 
antigen 4 
TRAIL TNF-related apoptosis-inducing ligand (Apo2L) 
VEGF Vascular endothelial growth factor 
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